<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100966</article-id><article-id pub-id-type="doi">10.7554/eLife.100966</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100966.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Ly6G<sup>+</sup> granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Priya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-4553-1512</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Raman Deep</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Binayak</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Panwar</surname><given-names>Varnika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Mrinmoy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Lakshya Veer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Neharika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chaturvedi</surname><given-names>Shivam</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6520-1191</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mehra</surname><given-names>Lalita</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rathee</surname><given-names>Aditya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shilpa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Foo</surname><given-names>Shihui</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>N</surname><given-names>Pavan Kumar</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Prasenjit</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Viswanathan</surname><given-names>Vijay</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kornfeld</surname><given-names>Hardy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8970-7306</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Howland</surname><given-names>Shanshan W</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Babu</surname><given-names>Subash</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nandicoori</surname><given-names>Vinay Kumar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5682-4178</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Singhal</surname><given-names>Amit</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7578-2930</contrib-id><email>dhiraj@icgeb.res.in</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j4rrt43</institution-id><institution>Cellular Immunology Group, International Centre for Genetic Engineering and Biotechnology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04fhee747</institution-id><institution>National Institute of Immunology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02dwcqs71</institution-id><institution>Department of Pathology, All India Institute of Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vmmgg57</institution-id><institution>Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR)</institution></institution-wrap><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036wvzt09</institution-id><institution>Infectious Diseases Labs (ID labs), Agency for Science, Technology and Research (A*STAR)</institution></institution-wrap><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03qp1eh12</institution-id><institution>Department of Immunology, ICMR-National Institute for Research in Tuberculosis</institution></institution-wrap><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff><aff id="aff7"><label>7</label><institution>Prof. M. Viswanathan Diabetes Research Center</institution><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Medicine, University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00x19de83</institution-id><institution>NIH-International Center of Excellence in Research</institution></institution-wrap><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043z4tv69</institution-id><institution>Laboratory of Parasitic Diseases, NIAID-NIH</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05shq4n12</institution-id><institution>Centre for Cellular and Molecular Biology</institution></institution-wrap><addr-line><named-content content-type="city">Hyderabad</named-content></addr-line><country>India</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02e7b5302</institution-id><institution>Lee Kong Chian School of Medicine, Nanyang Technological University (NTU)</institution></institution-wrap><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>05</day><month>02</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP100966</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-07-08"><day>08</day><month>07</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-07-10"><day>10</day><month>07</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.05.561061"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-25"><day>25</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100966.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-11-21"><day>21</day><month>11</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100966.2"/></event></pub-history><permissions><copyright-statement>© 2024, Sharma et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Sharma et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100966-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100966-figures-v1.pdf"/><abstract><p>The protective correlates of <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) infection-elicited host immune responses are incompletely understood. Here, we report pro-pathogenic crosstalk involving Ly6G<sup>+</sup> granulocytes (Ly6G<sup>+</sup>Gra), IL-17, and COX2. We show that in the lungs of <italic>Mtb</italic>-infected wild-type mice, either BCG-vaccinated or not, most intracellular bacilli are Ly6G<sup>+</sup>Gra-resident 4 weeks post-infection onwards. In the genetically susceptible <italic>ifng<sup>-/-</sup></italic> mice, excessive Ly6G<sup>+</sup>Gra infiltration correlates with severe bacteremia. Neutralizing IL-17 (anti-IL17mAb) and COX2 inhibition by celecoxib reverse Ly6G<sup>+</sup>Gra infiltration, associated pathology, and death in <italic>ifng<sup>-/-</sup></italic> mice. Surprisingly, Ly6G<sup>+</sup>Gra also serves as the major source of IL-17 in the lungs of <italic>Mtb</italic>-infected WT or <italic>ifng<sup>-/-</sup></italic> mice. The IL-17-COX2-Ly6G<sup>+</sup>Gra interplay also operates in WT mice. Inhibiting RORγt, the key transcription factor for IL-17 production or COX2, reduces the bacterial burden in Ly6G<sup>+</sup>Gra, leading to reduced bacterial burden and pathology in the lungs of WT mice. In the <italic>Mtb</italic>-infected WT mice, COX2 inhibition abrogates IL-17 levels in the lung homogenates and significantly enhances BCG’s protective efficacy, mainly by targeting the Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> pool, a phenotype also observed when IL-17 is blocked by RORγt inhibitor. Furthermore, in pulmonary TB patients, high neutrophil count and IL-17 correlated with adverse treatment outcomes. Together, our results suggest that IL-17 and PGE2 are the negative correlates of protection, and we propose targeting the pro-pathogenic IL-17-COX2-Ly6G<sup>+</sup>Gra axis for TB prevention and therapy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Mycobacterium tuberculosis</italic></kwd><kwd>neutrophils</kwd><kwd>correlates of protection</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03emtbt60</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/IC-06/003/91</award-id><principal-award-recipient><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03emtbt60</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/PR23092/NER/95/589/2017</award-id><principal-award-recipient><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03emtbt60</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/HRD/NBA-NWB/39/2020-21</award-id><principal-award-recipient><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04reqzt68</institution-id><institution>Wellcome Trust DBT India Alliance</institution></institution-wrap></funding-source><award-id>IA/S/17/1/503071</award-id><principal-award-recipient><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ffdsr55</institution-id><institution>Science and Engineering Research Board</institution></institution-wrap></funding-source><award-id>EMR/2016/005296</award-id><principal-award-recipient><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0492wrx28</institution-id><institution>Indian Council of Medical Research</institution></institution-wrap></funding-source><award-id>3/1/3/JRF-2017/HRD-LS/55193/79</award-id><principal-award-recipient><name><surname>Sharma</surname><given-names>Priya</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tjsyq23</institution-id><institution>Department of Biotechnology</institution></institution-wrap></funding-source><award-id>DBT/JRF/BET-18/I/2018/AL/160</award-id><principal-award-recipient><name><surname>Sharma</surname><given-names>Raman Deep</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The IL-17–Ly6G⁺ granulocyte axis is a key driver and correlate of tuberculosis pathology and represents a potential target for improving vaccine-induced protection and therapeutic outcomes.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tuberculosis (TB) is the major cause of mortality and morbidity due to an infectious disease. A lack of an effective vaccine, prognostic diversity among the patients, and the emergence of drug resistance greatly hamper the efforts to control TB. BCG, the only available vaccine, has limited efficacy in adults, although it works well in preventing childhood TB and TB meningitis. A comprehensive understanding of how the host immune system responds to vaccination, infection, and treatment is fundamental to the success of TB elimination programs (<xref ref-type="bibr" rid="bib11">Chandra et al., 2022</xref>).</p><p>Individuals exposed to <italic>Mtb</italic> follow a varied trajectory on parameters like developing latent or active disease, disease severity, and responsiveness to anti-TB chemotherapy (<xref ref-type="bibr" rid="bib4">Barry et al., 2009</xref>; <xref ref-type="bibr" rid="bib9">Cadena et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Dartois and Rubin, 2022</xref>; <xref ref-type="bibr" rid="bib35">Heyckendorf et al., 2021</xref>; <xref ref-type="bibr" rid="bib75">Pai et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Thompson et al., 2017</xref>). For example, the average treatment success rate for TB is ~80%, which is further lower in the case of drug-resistant TB (DR-TB, 50%) (<xref ref-type="bibr" rid="bib12">Chaves Torres et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Rockwood et al., 2016</xref>). Immunological features that contribute to treatment success and failure in TB patients present a unique opportunity to understand the host immunity associated with protection and pathogenesis against TB, respectively. The host-driven immunological mechanisms also play a critical role in the differential BCG responses, for example, contrasting T cell responses seen among young children and adults (<xref ref-type="bibr" rid="bib8">Brazier and McShane, 2020</xref>), which fade over time (<xref ref-type="bibr" rid="bib89">Soares et al., 2013</xref>). For intracellular pathogens like <italic>Mtb</italic>, the cell-mediated adaptive immune arm has been extensively explored for studying vaccine efficacy (<xref ref-type="bibr" rid="bib8">Brazier and McShane, 2020</xref>). However, since the bacteria mostly reside inside the innate immune cells, it is pertinent to ask whether innate immune-based mechanisms also contribute to the differential vaccine-induced protective responses.</p><p>A variety of innate immune cells are present in TB granulomas and play a role in pathogenesis and control. For example, in addition to macrophages, TB granulomas also comprise other innate immune cells, like granulocytes, dendritic cells, and unconventional cells like mesenchymal stem cells (MSCs), bone cells, adipocytes, etc (<xref ref-type="bibr" rid="bib9">Cadena et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Das et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Fatima et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Jain et al., 2020</xref>). Whether different cellular constituents confound the protective host responses remains poorly understood. The bacteria residing in the MSCs can escape immune cytokines like IFNγ and TNFα, which could effectively blunt the T-cell-mediated protective immune responses (<xref ref-type="bibr" rid="bib39">Jain et al., 2020</xref>). Similarly, neutrophils, the most extensively studied granulocytes in the context of TB (<xref ref-type="bibr" rid="bib17">Dallenga and Schaible, 2016</xref>; <xref ref-type="bibr" rid="bib46">Kimmey et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Lovewell et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Mishra et al., 2017</xref>) represent the most common <italic>Mtb</italic>-containing innate cells in the airways of active TB patients (<xref ref-type="bibr" rid="bib23">Eum et al., 2010</xref>). Studies over the past decade point to a more pathological role of neutrophils in TB (<xref ref-type="bibr" rid="bib6">Berry et al., 2010</xref>; <xref ref-type="bibr" rid="bib33">Han et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Lowe et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Nwongbouwoh Muefong et al., 2022</xref>; <xref ref-type="bibr" rid="bib65">Mayer-Barber, 2023</xref>), although some studies also report their protective roles in specific contexts (<xref ref-type="bibr" rid="bib61">Lowe et al., 2018</xref>; <xref ref-type="bibr" rid="bib64">Martineau et al., 2007</xref>; <xref ref-type="bibr" rid="bib88">Silva et al., 1989</xref>). Neutrophils are a diverse cell type; however, Ly6G<sup>+</sup> (both high and mid) granulocytes are the most studied subtype.</p><p>Using the mice model of TB, in this study, we explored neutrophils as a distinctive niche for <italic>Mtb</italic>. We report that Ly6G<sup>+</sup> neutrophils (Ly6<sup>+</sup>Gra) infiltration and resident <italic>Mtb</italic> within these cells correlate with disease severity. We show the establishment of an IL-17-Ly6G<sup>+</sup>Gra axis, supported by COX2 in disease pathology. Our results indicate that disrupting the COX2-IL17-Ly6G<sup>+</sup>Gra axis significantly enhances the preventive responses of BCG, enables better control in genetically vulnerable subjects, and provides an exciting opportunity for host-directed therapy against TB.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Neutrophils serve as the major niche for <italic>Mycobacterium tuberculosis</italic> in mice lungs</title><p>To assess diverse cellular niches in the lungs of <italic>Mtb</italic>-infected C57BL/6 (WT) mice, we investigated intracellular <italic>Mtb</italic> burden in Ly6G<sup>+</sup> CD11b<sup>+</sup> granulocytes (or Ly6G<sup>+</sup>Gra or PMNs), CD64<sup>+</sup>MerTK<sup>+</sup> macrophages and Sca1<sup>+</sup>CD90.1<sup>+</sup>CD73<sup>+</sup> mesenchymal stem cells (MSCs). The gating strategy for sorting these cells is shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Mice were infected with 100–200 H37Rv colony-forming units (CFUs) via aerosol challenge, and at 4, 8, and, 12 weeks post-infection (p.i.), the total bacterial burden in the lung and spleen was estimated by CFU enumeration (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–C</xref>). In addition, from the lungs, we flow-sorted Ly6G<sup>+</sup>Gra, macrophages, and MSCs following the gating strategy shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Among the three cell populations, MSCs were the most abundant cell type across each of the time points post<italic>-Mtb</italic> infection (2–6x10<sup>4</sup>/million sorted cells/half lung), followed by macrophages (4–9x10<sup>3</sup>/million sorted cells) and Ly6G<sup>+</sup>Gra (1–4x10<sup>3</sup> / million sorted cells, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). However, Ly6G<sup>+</sup>Gra contained, on average, four to five times more total bacillary load (from the total sorted pool of cells) as compared to either macrophages or MSCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). To account for the differences in the total cell number obtained for the three cell types, we calculated CFU/10<sup>4</sup> cells, which showed the highest bacillary load in the Ly6G<sup>+</sup>Gra (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Tissue sections from the lungs of <italic>Mtb</italic>-infected mice also showed co-staining of Ly6G with Ag85B, the <italic>Mtb</italic> surface antigen (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Thus, our data suggest that a large number of <italic>Mtb</italic> in the lungs of infected animals reside inside the Ly6G<sup>+</sup>Gra, which outnumber those present in macrophages or MSCs.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>PMNs harbors substantial amounts of <italic>Mtb</italic> and provide an immune-privileged niche to <italic>Mtb</italic>.</title><p>(<bold>A</bold>) FACS gating strategy used to sort PMNs, macrophages, and MSCs from the lungs of mice. (<bold>B</bold>) <italic>Mtb</italic> burden in individual sorted cells (PMNs, macrophages, and MSCs), plotted as CFU/10<sup>4</sup> sorted cells from the lungs of <italic>Mtb</italic>-infected mice at 4-, 8-, and 12 weeks post-infection time point. A two-way ANOVA statistical test was applied to compare all the groups at different time points. Sample size (n)=5 mice at each time point. (<bold>C</bold>) IFA images of the lungs of <italic>Mtb</italic>-infected mice showing the co-localization of PMNs (Ly6G<sup>+</sup> cells shown in red color) and <italic>Mtb</italic> antigen Ag85B (shown in green color). (<bold>D</bold>) Study design for BCG vaccination experiment. C57BL/6 mice were vaccinated intradermally with 10<sup>6</sup> BCG bacilli, followed by aerosol infection with H37Rv (100–200 CFU) 8 weeks post-BCG vaccination. At 4, 8, and 12 weeks post-infection, mice were euthanized for various studies. (<bold>E</bold>) Determination of <italic>Mtb</italic> burden in individual sorted cells, plotted as CFU/10<sup>4</sup> sorted cells at 4, 8, and 12 weeks post-infection, from the lungs of vaccinated and unvaccinated mice. Experimental groups were evaluated using a two-way ANOVA statistical test. Sample size (n)=5 mice/group in all treatment groups. This BCG vaccination experiment was carried out independently in two distinct experimental replicates. (<bold>F</bold>) Venn diagram highlighting the number of common and unique differentially expressed genes (DEGs) from each pairwise comparison between BCG vaccinated +infected, only infected, and uninfected controls (<bold>G</bold>) z-scaled expression of the DEGs corresponding to the significantly enriched Gene Ontology Biological processes obtained using gene set co-regulation analysis of the DEGs (<bold>H</bold>) highlights the enriched KEGG pathways based on gene set co-regulation analysis of the DEGs. Within the plotGesecaTable() function, z-scores are first calculated for each normalized gene expression across the dataset. For each GO BP/KEGG pathway, the expression of its corresponding genes are summed up per sample and scaled and defined within the range of –2 to 2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>PMNs harbor a substantial amount of <italic>Mtb</italic>.</title><p>(<bold>A</bold>) Schematic representation of the study design and experimental timeline. C57BL/6 mice were infected with H37Rv, and at 4, 8, and 12 weeks post-infection, mice were sacrificed for various studies. Bacterial burden in (<bold>B</bold>) Lung and (<bold>C</bold>) Spleen of infected mice at 4, 8, and 12 weeks post<italic>-Mtb</italic> infection. (<bold>D</bold>) Bar graphs showing the numbers of sorted lung cells (PMNs, macrophages, and MSCs), normalized to per 1 million of total acquired cells at 4, 8, and 12 weeks post-infection. (<bold>E</bold>) Representative absolute CFU count present inside total sorted PMNs, macrophages, and MSCs from the lung. Experimental groups were evaluated using a two-way ANOVA and one-way ANOVA statistical test, respectively. Sample size (n)=5 mice/group in all mice groups. (<bold>F</bold>) Time course of the lung and spleen bacterial burden in unvaccinated and BCG-vaccinated groups. An unpaired student’s t-test was applied to compare both experimental groups at different time points. (<bold>G</bold>) Representative H&amp;E-stained lung sections showed less pathology in the BCG-vaccinated group compared to the unvaccinated group. (<bold>H</bold>) Quantification of the sorted cells normalized to per 1 million of total acquired cells from the lungs of vaccinated and unvaccinated mice. Experimental groups were evaluated using a two-way ANOVA statistical test, n=5 mice/group in both groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>The residual <italic>Mtb</italic> population in BCG-vaccinated animals is largely Ly6G<sup>+</sup>Gra- or PMN-resident</title><p>To understand the relevance of Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> and its contribution towards TB pathogenesis, we repeated the above experiments in BCG-vaccinated animals. Mice were administered either PBS or BCG (Pasteur strain) intradermally, followed by aerosol challenge with H37Rv at 8 weeks post-BCG vaccination (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). As expected, animals that received BCG showed nearly 10-fold lower bacterial burden in the lungs and spleen compared to the unvaccinated PBS controls (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). Consequently, BCG-vaccinated animals also showed less pathology than the unvaccinated PBS controls (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Among the sorted cells from the lungs, except for a marginal decline in Ly6G<sup>+</sup>Gra number at 8 weeks p.i. in the BCG-vaccinated group, the relative distribution of PMNs, macrophages, and MSCs in both control and BCG-vaccinated animals remained unchanged over the course of infection (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). The <italic>Mtb</italic> burden, however, in each of the three cell types dropped significantly (by 80–90%) in the BCG-vaccinated animals compared to the unvaccinated animals (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Interestingly, lung Ly6G<sup>+</sup>Gra in BCG-vaccinated mice still contained 10–20-fold (~log<sub>10</sub> 1-1.5 fold) more bacilli compared to the other two cell types for each time point p.i. investigated (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These results indicate that BCG-induced protective host immunity, despite being effective, was not sufficient to clear the Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> population, unlike the <italic>Mtb</italic> pools present in MSCs or macrophages. Thus, we inferred that Ly6G<sup>+</sup>Gra serve as a preferred niche for <italic>Mtb</italic> to withstand host immunological assaults in mice.</p></sec><sec id="s2-3"><title>RNAseq analysis of Ly6G<sup>+</sup>Gra sorted from the lungs of <italic>Mtb</italic>-infected animals</title><p>We next analyzed the global gene expression profile of flow-sorted Ly6G<sup>+</sup>Gra from the lungs of unvaccinated or BCG-vaccinated mice, either uninfected or <italic>Mtb</italic>-infected (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Only 27 differentially expressed genes (DEGs) were found between unvaccinated, uninfected (UI) and BCG-vaccinated, uninfected animals, and therefore, the BCG-vaccinated, uninfected mice group was excluded from the further analysis (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Compared to the UI control group, 944 genes were DEGs in the <italic>Mtb</italic>-infection group alone (Rv, blue circle), whereas there were 620 DEGs in the BCG-vaccinated <italic>Mtb</italic>-infected group (red circle), 373 genes being common to both the lists (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Compared to the <italic>Mtb</italic>-infected group, the BCG-vaccinated <italic>Mtb</italic>-infected group had 209 DEGs (green circle, <xref ref-type="fig" rid="fig1">Figure 1F</xref>). A gene set co-regulation analysis (GESECA, see methods) among DEGs across the three groups showed enrichment of Gene Ontology Biological Processes (GO-BP) unsaturated fatty-acid biosynthesis in <italic>Mtb</italic>-infected group alone (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). This included genes like <italic>Sirt1</italic>, <italic>FadS3</italic>, <italic>IL1b</italic>, <italic>Scd1</italic>, <italic>Scd2</italic>, and <italic>Alox15</italic> (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). In the BCG-vaccinated and <italic>Mtb</italic>-infected group (BCG +<italic>Mtb</italic>), GO-BPs such as positive regulation of cell division, CD4<sup>+</sup>T cell cytokine production, and eicosanoid biosynthetic process were upregulated (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). We also investigated the enrichment of KEGG pathways in DEGs and found Th17 cell differentiation, cytosolic DNA sensing pathway, ferroptosis, and necroptosis pathways to be upregulated in the <italic>Mtb</italic>-infected group but downregulated in the BCG +<italic>Mtb</italic> group (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Th17 cell chemotaxis has been associated with exacerbated TB pathology, and therefore, a decline in this pathway in the BCG-vaccinated group concurred with earlier studies (<xref ref-type="bibr" rid="bib40">Jung et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Basile et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Jurado et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Mills, 2023</xref>). Together, the results from RNAseq analysis reveal the potential roles of the eicosanoid and IL-17 signaling pathways in regulating the Ly6G<sup>+</sup>Gra-mediated effects in TB.</p></sec><sec id="s2-4"><title>Association of Ly6G<sup>+</sup>Gra with severe TB pathology in <italic>ifng<sup>-/-</sup></italic> mice</title><p>The results so far demonstrate a possible role of Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> in TB pathology. To further investigate the mechanism of Ly6G<sup>+</sup>Gra-driven pathology, we used <italic>ifng<sup>-/-</sup></italic> animals, which are known to develop severe neutrophilia and pathology upon <italic>Mtb</italic> infection (<xref ref-type="bibr" rid="bib15">Cooper et al., 1993</xref>; <xref ref-type="bibr" rid="bib28">Flynn et al., 1993</xref>; <xref ref-type="bibr" rid="bib79">Pearl et al., 2001</xref>). We first verified the disease severity in <italic>Mtb</italic>-infected WT or <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The <italic>ifng<sup>-/-</sup></italic> mice, compared to the WT mice, showed severe gross lung pathology (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and a very high <italic>Mtb</italic> burden in the lungs and spleen (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), compared to WT mice, which was associated with high mortality (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Histopathology analysis revealed massive infiltration of the immune cells in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Immunofluorescence staining of lung sections and flow cytometric analysis of the lung cells showed that most of the lung immune cells in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice were Ly6G<sup>+</sup>Gra (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). Unlike in the <italic>Mtb</italic>-infected <italic>WT</italic> mice, Ly6G<sup>+</sup>Gra recruitment followed a time-dependent increase in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice, increasing from ~26% at four weeks to ~61% at 10 weeks p.i. (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). This increase was also reflected in the total Ly6G<sup>+</sup>Gra sorted from the lungs of these mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). On average, <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice showed a nearly 40-fold higher number of Ly6G<sup>+</sup>Gra than the <italic>Mtb</italic>-infected WT animals (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Moreover, Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> burden also increased several folds in the <italic>ifng<sup>-/-</sup></italic> compared to the WT mice at 10 weeks p.i. (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Thus, massive infiltration of Ly6G<sup>+</sup>Gra and a very high intracellular <italic>Mtb</italic> burden in those cells correlated with severe pathology in <italic>ifng<sup>-/-</sup></italic> mice.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Uncontrolled neutrophilia, huge <italic>Mtb</italic> burden, severe disease pathology, and death in <italic>ifng<sup>-/-</sup></italic> mice is mediated by high IL-17.</title><p>(<bold>A</bold>) Experimental design and timeline. C57BL/6 mice (WT and <italic>ifng</italic><sup><italic>-/-</italic></sup>) were infected with H37Rv, 100 CFU, via the aerosol route. Mice from both groups were euthanized at 4, 7, and 10 weeks post-infection time point. Lung and spleen tissues were harvested and processed for diverse assays, as shown in the study design. (<bold>B</bold>) H&amp;E-stained lung sections of WT and <italic>ifng<sup>-/-</sup></italic> mice at ×10 magnification, showing severe histopathology in the latter group of mice. (<bold>C</bold>) Lung IFA images from the same group of mice showing the extensive infiltration of PMNs (Ly6G<sup>+</sup> cells stained in red color) in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice compared to WT mice. (<bold>D</bold>) Representative FACS dot plot showing the percentage of PMNs in the lungs of <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice (population is gated on CD45<sup>+</sup> cells). Percentage of PMNs in the lungs of <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice (population is gated on CD45<sup>+</sup> cells) is shown at the right. (<bold>E</bold>) <italic>Mtb</italic> burden in the PMNs, sorted from the lung of <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic>, plotted as CFU/10<sup>4</sup> sorted cells at 4, 7, and 10 weeks post-infection. Experimental groups were evaluated using a two-way ANOVA statistical test. Sample size (n)=5–6 mice/group in both the groups. Luminex data: Quantification of several cytokines and chemokines from the lung supernatant of uninfected and <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice. (<bold>F</bold>) Cytokines and chemokines that are upregulated in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice compared to WT mice (<bold>G</bold>) Cytokines and chemokines that are downregulated in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice compared to WT mice. Data were evaluated using a two-way ANOVA statistical test. Sample size (n)=5–6 mice/group in all the groups. This experiment was performed only once as a single experimental replicate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Contribution of neutrophilia to the severity of TB disease.</title><p>WT and <italic>IFNγ <sup>-/-</sup></italic>mice were infected with H37Rv, 100 CFU, via the aerosol route. Mice from both groups were euthanized at 4, 7, and 10 weeks post-infection time point. Lung and spleen tissues were harvested and processed for diverse assays, as shown in the study design in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>A</bold>) Lung pictures from <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice showing the disease pathology. (<bold>B</bold>) Enumeration of lung and spleen bacterial <italic>burden</italic> in WT and <italic>ifng<sup>-/-</sup></italic> mice, 4, 7, and 10 weeks post-infection, n=5–6 mice per experimental group. A two-way ANOVA statistical test was applied to compare lung and spleen CFU all in WT and <italic>ifng<sup>-/-</sup></italic> at different time points post-infection. (<bold>C</bold>) Survival curve of WT and <italic>ifng<sup>-/-</sup></italic> following <italic>Mtb</italic> infection. Both strains of mice were infected with 100–200 CFU of H37Rv through an aerosol route followed by incubation till their natural death. The time of death of each mouse was noted and plotted for the survival analysis (n=12 mice/group). (<bold>D</bold>) Count of PMNs, normalized to 1 million of total acquired cells, in the lungs of infected WT and <italic>ifng<sup>-/-</sup></italic> mice at 4, 7, and 10 weeks post-infection. n=5–6 mice per experimental group. Two-way ANOVA statistical test was applied to compare groups at different time points post-infection (<bold>E</bold>) Luminex data: A panel of 36 cytokines and chemokines was quantified from the lung supernatant of uninfected and <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice. All the upregulated and downregulated cytokines and chemokines were compared pairwise between two treatment groups and plotted in the form of a heat map. (<bold>F</bold>) Lung cells from uninfected WT mice were stained with different antibodies and assayed through flow cytometry to elucidate the cellular source and levels of IL-17 in uninfected mice. Plots showing pooled samples from three mice. (<bold>G</bold>) Number of CD11b<sup>-</sup>Ly6G<sup>-</sup> IL-17<sup>+</sup> granulocytes in the lungs of uninfected and <italic>Mtb</italic>-infected mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Severe TB pathology in <italic>ifng<sup>-/-</sup></italic> mice correlated with increased lung IL-17 levels</title><p>To understand what might have resulted in the increased Ly6G<sup>+</sup>Gra infiltration in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> animals, we analyzed cytokine/chemokine levels in the lung homogenates. Several cytokines/chemokines were significantly dysregulated in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice compared to the <italic>Mtb</italic>-infected WT mice (<xref ref-type="fig" rid="fig2">Figure 2F–G</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Among those, CXCL1, CXCL2, IL-1β, IL-1α, IL-6, IL-17A (or IL-17), M-CSF, CCL3, and TNFα were significantly upregulated in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> compared to the <italic>Mtb</italic>-infected WT mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). On the contrary, IFNγ, IL-12, IL-9, IL-10, IL-15, IL-18, IL-27, and IL-28 were downregulated in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Among the upregulated cytokines in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> animals, CXCL1 and CXCL2 are the known chemo-attractants for PMNs recruitment (<xref ref-type="bibr" rid="bib47">Kolaczkowska and Kubes, 2013</xref>), whereas IL-1α, IL-1β, and IL-6 are key players in the differentiation and expansion of the Th17 cells (<xref ref-type="bibr" rid="bib44">Ketelut-Carneiro et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Lee et al., 2010</xref>; <xref ref-type="bibr" rid="bib66">Mills, 2023</xref>). Interestingly, IL-17, a classical pro-inflammatory cytokine predominantly secreted by the Th17 cells, was also significantly upregulated in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Increased IL-17 in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice concurred with earlier reports which show a key role for IL-17 in TB disease pathology (<xref ref-type="bibr" rid="bib16">Cruz et al., 2010</xref>).</p></sec><sec id="s2-6"><title>Ly6G<sup>+</sup>Gra are the key source of IL-17 in TB granulomas</title><p>IL-17 is important for TB pathology (<xref ref-type="bibr" rid="bib66">Mills, 2023</xref>), and also for the recruitment and activation of neutrophils (<xref ref-type="bibr" rid="bib1">Allen et al., 2015</xref>). For Th17 cell effector function and to sustain a high level of IL-17 production, another cytokine, IL-23, is required (<xref ref-type="bibr" rid="bib32">Haines et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Langrish et al., 2005</xref>; <xref ref-type="bibr" rid="bib93">Teng et al., 2015</xref>). However, in our cytokine analysis, we did not observe any increase in IL-23 production in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Interestingly, IL-23-independent Th17 differentiation and maintenance is also known, which typically is mediated by PGE2 (<xref ref-type="bibr" rid="bib34">Hernandez et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Paulissen et al., 2013</xref>). Also, PGE2 synergizes with IL-23 to promote the expansion of Th17 cells (<xref ref-type="bibr" rid="bib13">Chizzolini et al., 2008</xref>). While IL-23 did not show an increase, we observed that there was significantly more PGE2 in the lung homogenates of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Interestingly, both the IL-17 pathway and eicosanoid pathway were also enriched in the neutrophil’s RNAseq analysis (<xref ref-type="fig" rid="fig1">Figure 1G–H</xref>). Thus, we wondered whether cells other than Th17 could be responsible for increased IL-17 production. We analyzed the IL-17-producing cells in the lungs of uninfected (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>) or <italic>Mtb</italic>-infected WT mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In the CD45<sup>+</sup>CD11b<sup>-</sup>Ly6G<sup>-</sup> population, which mostly represented adaptive immune cells like T cells, B cells, NK cells, etc, &lt;100 cells were positive for IL-17 in the uninfected mice, which increased to about 4000 cells upon infection, representing about &lt;1% of this pool of cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F–G</xref>). In contrast, in the CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> cellular pool, 70–80% of cells were positive for IL-17, showing about &lt;2000 cells in the uninfected mice compared to &gt;13,000 cells in the <italic>Mtb</italic>-infected mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). Immunofluorescence analysis of lung sections from <italic>Mtb</italic>-infected WT mice revealed similar observations when stained for CD4 and IL-17. While we could witness CD4 and IL-17 co-expressing cells, several IL-17<sup>+</sup> cells lacked CD4 expression (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Staining for Ly6G and IL-17 revealed intense IL-17 and Ly6G co-staining in the lung tissue sections of <italic>Mtb</italic>-infected WT mice, suggesting Ly6G<sup>+</sup>Gra cells as the main source of lung IL-17 (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). A similar IL-17 and Ly6G co-staining was also observed in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Interestingly, even in human TB granulomas, we observed considerable co-staining of CD66b (the human neutrophil marker) and IL-17 (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Together, our data indicate that during <italic>Mtb</italic> infection, an active IL-17-Ly6G<sup>+</sup>Gra axis gets established, which may contribute to TB pathology.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PMNs are one of the major sources of IL-17 in the lungs of <italic>Mtb-</italic>infected mice.</title><p>(<bold>A</bold>) Levels of IL-23 in the lung supernatant of uninfected and <italic>Mtb</italic>-infected WT and <italic>ifng<sup>-/-</sup></italic> mice. (<bold>B</bold>) PGE2 levels in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice compared to uninfected control. An unpaired student’s t-test was applied to calculate the significance between the two groups. (<bold>C</bold>) Lung cells from <italic>Mtb</italic>-infected WT mice were stained with different antibodies and assayed through flow cytometry to elucidate the cellular source for elevated IL-17. FACS gating strategy showing PMNs (Ly6G<sup>+</sup> CD11b<sup>+</sup> cells) and Ly6G<sup>-</sup> CD11b<sup>-</sup> cells showing IL-17 positivity in the lungs of <italic>Mtb</italic>-infected mice. (<bold>D</bold>) Number of Ly6G<sup>+</sup> IL-17<sup>+</sup> granulocytes in the lungs of uninfected and <italic>Mtb</italic>-infected mice. (<bold>E</bold>) IFA images of the lungs of <italic>Mtb</italic>-infected WT mice at 6 weeks post-infection time point showing the co-localization of CD4<sup>+</sup> T cells (shown in red color) with IL-17 (shown in green color). The quantification of the CD4<sup>+</sup> cells, IL-17<sup>+</sup> cells, and double-positive IL-17<sup>+</sup> CD4<sup>+</sup> cells is presented as the proportion of DAPI<sup>+</sup> cells. (<bold>F</bold>) IFA images of the lungs of <italic>Mtb</italic>-infected WT mice at 6 weeks post-infection time point showing the co-localization of Ly6G<sup>+</sup> Gra (shown in red color) with IL-17 (shown in green color). The quantification of the Ly6G<sup>+</sup> cells, IL-17<sup>+</sup> cells, and double-positive IL-17<sup>+</sup> Ly6G<sup>+</sup> cells is presented as the proportion of DAPI<sup>+</sup> cells. (<bold>G</bold>) IFA images of the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice at 6 weeks post-infection time point showing the co-localization of PMNs (Ly6G<sup>+</sup> cells shown in red color) and IL-17 (shown in green color). The quantification of the Ly6G<sup>+</sup> cells, IL-17<sup>+</sup> cells, and double-positive IL-17<sup>+</sup> Ly6G<sup>+</sup> cells is presented as the proportion of DAPI<sup>+</sup> cells. (<bold>H</bold>) Co-localization of PMNs (CD66b<sup>+</sup> cells shown in red color) and IL-17 (shown in green color) in the gut granuloma section of intestinal TB (ITB) patients. The quantification of the CD66b<sup>+</sup> cells, IL-17<sup>+</sup> cells, and double-positive IL-17<sup>+</sup> CD66b<sup>+</sup> cells is presented as the proportion of DAPI<sup>+</sup> cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig3-v1.tif"/></fig></sec><sec id="s2-7"><title>Targeting IL-17 and PGE2 pathways controls bacterial burden and disease pathology in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice</title><p>The impact of IL-17 on TB pathogenesis is not unequivocally established. For example, IL-17 is believed to exacerbate TB pathology during the chronic phase of infection, partly through excessive neutrophil recruitment (<xref ref-type="bibr" rid="bib96">Torrado and Cooper, 2010</xref>). On the other hand, a more protective role of IL-17 in the WT mice was reported when infected with a hypervirulent strain of <italic>Mtb</italic> (<xref ref-type="bibr" rid="bib22">Domingo-Gonzalez et al., 2017</xref>). In addition, PGE2 works contrastingly towards IL-17 and IFNγ production by T cells, increasing the levels of IL-17 (<xref ref-type="bibr" rid="bib73">Napolitani et al., 2009</xref>). Since the results in the above sections suggested a pro-pathogenic role of IL-17 and PGE2, we decided to neutralize IL-17 and inhibit PGE2 in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice. To inhibit PGE2 biosynthesis, we decided to block the upstream enzyme COX2, which shifts the arachidonate flux towards 5-LO, leading to increased leukotriene production (<xref ref-type="bibr" rid="bib30">Funk, 2001</xref>). The <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice were administered anti-IL-17 monoclonal Ab (mAb) intra-peritoneally every 3–4 days, starting a day before the infection (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). For both isotype control mAb and anti-IL17 mAb arm, celecoxib (50 mg/kg) treatment was initiated 3 weeks p.i. (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). A significant decline in IL-17 levels in the lung homogenates was observed in anti-IL-17 mAb-administered mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Celecoxib alone had no significant impact on IL-17 levels in <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Combining anti-IL-17 mAb with celecoxib showed a similar decline in IL-17 levels as was noted in the anti-IL-17 mAb group alone (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Neutralizing IL-17 led to a significant decline in the number of infiltrating Ly6G<sup>+</sup>Gra in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Interestingly, celecoxib treatment alone also efficiently reduced the number of infiltrating Ly6G<sup>+</sup>Gra (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). However, the combined treatment with anti-IL-17 mAb and celecoxib had no synergistic effect (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). While IL-17 neutralization and celecoxib treatment alone reduced Ly6G<sup>+</sup>Gra recruitment in the lungs, these treatments alone could not bring down the <italic>Mtb</italic> burden in the lung Ly6G<sup>+</sup>Gra from <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). However, their combination significantly reduced the <italic>Mtb</italic> burden in the lung Ly6G<sup>+</sup>Gra from <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). A similar trend was also seen for the whole lung CFU, where anti-IL17 mAb or celecoxib alone could not significantly reduce the <italic>Mtb</italic> burden, the combined treatment showed significant decline in <italic>Mtb</italic> population (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Unlike in the lungs, or sorted Ly6G<sup>+</sup>Gra from the lungs, IL-17 neutralization alone was sufficient to reduce bacterial burden in the spleen (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), indicating Ly6G<sup>+</sup>Gra’s potential role in <italic>Mtb</italic> dissemination. We also noticed a significant rescue in the survival of <italic>ifng<sup>-/-</sup></italic> mice by combined IL-17 neutralization and celecoxib treatment (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). This aligned with reduced lung pathology in anti-IL-17 mAb and celecoxib-treated <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Further analysis of the Ly6G<sup>+</sup> cell population revealed a significant population of CD11b<sup>mid</sup>Ly6G<sup>hi</sup> cells in the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice, which typically reflects an immature neutrophil population (<xref ref-type="bibr" rid="bib85">Scapini et al., 2016</xref>; <xref ref-type="fig" rid="fig4">Figure 4H</xref>). A reduction in this population coincided with the protective effects of anti-IL-17 mAb and celecoxib treatment. However, such distinction was not very apparent in the WT mice. Taken together, our data suggest the protective effects of combined treatment with anti-IL-17 mAb and celecoxib in TB by reducing the Ly6G<sup>+</sup>Gra population.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Celecoxib treatment with IL-17 neutralization reverses IL-17-dependent neutrophilia and controls TB disease in <italic>ifng<sup>-/-</sup></italic> mice.</title><p>(<bold>A</bold>) Study plan. <italic>IFNγ <sup>-/-</sup></italic>C57BL/6 mice infected with H37Rv at a dose of 100 CFU via the aerosol route. One arm of the <italic>Mtb</italic>-infected mice received an αIL-17 neutralizing antibody (100 µg/mouse), and the other arm received an isotype control antibody (100 µg/mouse) intraperitoneally twice in a week, starting a day before <italic>Mtb</italic> infection. After 3 weeks of infection, both groups of mice were further divided into two groups, one that received celecoxib (50 mg/kg, orally) for 3 weeks and the other that received vehicle control (DMSO here). Mice from all four groups of mice were euthanized at 6 weeks post<italic>-Mtb</italic> infection, and their lungs and spleen were harvested, and serum was stored for ELISA. (<bold>B</bold>) PMN count, normalized to 1 million total acquired cells, in the lungs of infected mice in all four treatment groups at 6 weeks post-infection. (<bold>C</bold>) CFU (normalized to per 10<sup>4</sup> sorted cells) inside PMNs sorted out from the lungs of infected mice at 6 weeks post-infection sacrifice. Bacterial burden in lung (<bold>D</bold>) and spleen (<bold>E</bold>) of <italic>Mtb</italic>-infected mice from described treatment groups at 6 weeks post-infection time point sacrifice. The statistical significance of the treatment groups was assessed by applying a one-way ANOVA test. (n=3–4 mice/group). This experiment was performed only once as a single experimental replicate. (<bold>F</bold>) Survival curve of the group of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice that received αIL-17 neutralizing antibody, celecoxib alone or together, along with the untreated control group and infected WT mice group. Both mice strains were infected with 100 CFU of H37Rv through an aerosol route. One arm of the <italic>Mtb</italic>-infected mice received an αIL-17 neutralizing antibody, and the other arm received an isotype control antibody twice a week, starting a day before the <italic>Mtb</italic> infection. After 3 weeks of infection, both groups of mice were further divided into two groups, one that received celecoxib for 3 weeks and the other that received vehicle control (DMSO). Mice were incubated till their natural death. The time of death of each mouse was noted and plotted for survival analysis (n=7 mice/group). This experiment was performed only once as a single experimental replicate. (<bold>G</bold>) H&amp;E-stained lung sections and granuloma scoring showing lung pathology from all four treatment groups. (<bold>H</bold>) Lung IFA images from the above-stated treatment groups of mice show the colocalization (yellow) of PMNs (Ly6G<sup>+</sup> cells shown in red color) and IL-17 (shown in green color). (<bold>I</bold>) Representative FACS dot plot showing the percentage of PMNs in the lungs of <italic>Mtb</italic>-infected mice in all four above-stated treatment groups (population is gated on CD45<sup>+</sup> cells). This also shows the presence of a distinct CD11b<sup>mid</sup> Ly6G<sup>hi</sup> population in the isotype control group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>IL-17 neutralization synergizes with COX-2 inhibition and controls TB disease in <italic>ifng<sup>-/-</sup></italic> mice.</title><p>Study plan (as shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>): <italic>ifng<sup>-/-</sup></italic> C57BL/6 mice infected with H37Rv at a dose of 100 CFU via the aerosol route. One arm of the <italic>Mtb</italic>-infected mice received an αIL-17 neutralizing antibody (100 µg/mouse), and the other arm received an isotype control antibody (100 µg/mouse) intraperitoneally twice in a week, starting a day before <italic>Mtb</italic> infection. After 3 weeks of infection, both groups of mice were further divided into two groups, one that received celecoxib (50 mg/kg, orally) for 3 weeks and the other that received vehicle control (DMSO here). Mice from all four groups of mice were euthanized at 6 weeks post<italic>-Mtb</italic> infection, and their lungs and spleen were harvested, and serum was stored for ELISA. (<bold>A</bold>) Lung IL-17 levels in all four mice treatment groups as explained above along with uninfected control. (<bold>B</bold>) %Th<sub>17</sub> cells (gated on CD4<sup>+</sup> T cells) in the lungs of mice from the same treatment groups described above. The statistical significance of the treatment groups was assessed by applying a one-way ANOVA test. n=3–4 mice/group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Pathological role of Ly6G<sup>+</sup>Gra-derived IL-17 in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> animals</title><p>We next investigated the effect of IL-17 neutralization or celecoxib treatment on lung IL-17-producing cells in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice. We first assessed the number of IL-17-positive T helper cells (Th17) in the single-cell preparations from the lungs. While there was a trend of a decline in the number of Th17 cells upon either IL-17 neutralization alone or in combination to COX2 inhibition in the lungs of <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice, those changes were not found significant (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). In the lung sections stained for IL-17 along with Ly6G, IL-17 neutralization, either alone or combined with COX2 inhibition, led to a consistent decline in IL-17<sup>+</sup> Ly6G<sup>+</sup> cells (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). The results from IL-17 ELISA in the lung homogenates, Th17 cell count in the lungs, and IL-17-Ly6G co-staining together suggest that while IL-17 contributes to high Ly6G<sup>+</sup>Gra infiltration, it is the Ly6G<sup>+</sup>Gra that produces IL-17 locally, thereby establishing a vicious loop.</p></sec><sec id="s2-9"><title>Pathological role of Ly6G<sup>+</sup>Gra-IL-17 axis in WT animals</title><p>The WT animals also show an increase in IL-17 levels upon <italic>Mtb</italic> infection, albeit to a lower magnitude than the <italic>ifng<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Moreover, as noted in <xref ref-type="fig" rid="fig3">Figure 3F</xref>, the WT mice also showed substantial IL-17-Ly6G co-staining. Hence, we asked whether a similar IL-17-Ly6G<sup>+</sup>Gra axis could also be operating in the <italic>Mtb</italic>-infected WT animals and contribute to sustained Ly6G<sup>+</sup>Gra-resident pool of <italic>Mtb</italic> in the lungs. To test this hypothesis, we decided to inhibit IL-17 in <italic>Mtb</italic>-infected WT mice. Instead of using anti-IL-17, we decided to use SR2211 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), a pharmacological inhibitor of RORγt (inverse agonist), the main transcription factor for IL-17 expression (<xref ref-type="bibr" rid="bib6">Berry et al., 2010</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2013</xref>), which may provide improved clinical benefits compared to anti-IL-17 mAb (<xref ref-type="bibr" rid="bib51">Lamb et al., 2021</xref>). We also included the celecoxib group since <italic>Mtb</italic>-infected WT mice also show very high PGE2 levels in the lung homogenates (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Treatment with SR2211 led to a significant decline in IL-17 levels in the lung homogenates of <italic>Mtb</italic>-infected WT mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Interestingly, unlike the <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice, celecoxib alone was also able to reduce the level of IL-17 in the lung homogenates of <italic>Mtb</italic>-infected WT mice, and so was the combination of both SR2211 and celecoxib (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Treatment with SR2211 showed a downward trend in Ly6G<sup>+</sup>Gra count in the lungs; however, the differences were not significant (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). At the whole tissue level, SR2211 alone did not reduce the <italic>Mtb</italic> burden in the lungs significantly (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). However, it was highly efficient in controlling dissemination to the spleen (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Similarly, celecoxib treatment, either alone or in combination with SR2211, significantly reduced bacterial CFUs in the lung and spleen; however, the effects were more pronounced in the spleen (<xref ref-type="fig" rid="fig5">Figure 5F–G</xref>). Furthermore, SR2211 and celecoxib, either alone or in combination, led to a significant decline in the Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> population (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). The histopathology analysis of the lungs reflected the protective effects of SR2211 and celecoxib (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B–C</xref>). Moreover, SR2211 treatment also led to a loss of IL-17-Ly6G co-staining, indicating the role of Ly6G<sup>+</sup>Gra-derived IL-17 in disease pathology in the WT mice (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). These results in the WT mice further emphasize the establishment of the IL-17- Ly6G<sup>+</sup>Gra axis during <italic>Mtb</italic> infection and demonstrate its role in TB pathology and disease.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>RORγt inhibition reduces mycobacterial burden and neutrophil infiltration in the lungs of <italic>Mtb</italic>-infected mice.</title><p>(<bold>A</bold>) IL-17 levels in the lung homogenates of uninfected and <italic>Mtb</italic>-infected WT mice. An unpaired student’s t-test was applied to calculate significance between the two groups. Sample size (n)=5–6 mice/group (<bold>B</bold>) Study plan. C57BL/6 mice were infected with H37Rv at a 100–200 CFU dose via the aerosol route. At 3 weeks post-infection, treatment with celecoxib and SR 2211 (inverse agonist for RORγt) was started for a further 3 weeks. Celecoxib (50 mg/kg) was administered orally once a day, and SR 2211 (20mg/kg) was administered intraperitoneally thrice in a week. At 6 weeks post-infection, mice from the treatment and untreated control groups were sacrificed, lung and spleen were harvested for CFU, histopathology, and FACS analysis, and lung homogenates were stored for ELISA. (<bold>C</bold>) PGE2 levels in the lung homogenates of uninfected and <italic>Mtb</italic>-infected WT mice at 4 and 12 weeks post-infection time point. Unpaired student’s t-test was applied to calculate significance between the two groups at each time point. Sample size (n)=3–4 mice/group. (<bold>D</bold>) Levels of IL-17 in the lung homogenates of all four-treatment groups of mice. The statistical significance of the treatment groups was assessed by applying a one-way ANOVA test, n=3–4 mice/group. (<bold>E</bold>) Representative FACS dot plot showing the percentage of PMNs in the lungs of <italic>Mtb</italic>-infected mice in all four above-stated treatment groups (population is gated on CD45<sup>+</sup> cells). Mycobacterial burden in the lung (<bold>F</bold>) and spleen (<bold>G</bold>), in the above-stated treatment groups of mice. (<bold>H</bold>) Lung PMNs <italic>Mtb</italic> burden normalized to per 10<sup>4</sup> sorted cells in all four treatment groups of mice. The statistical significance of the treatment groups was assessed by applying a one-way ANOVA test, n=5 mice/group. (<bold>I</bold>) Lung IFA images from the above-stated treated group of mice show the colocalization of PMNs (Ly6G<sup>+</sup> cells shown in red color) and IL-17 (shown in green color). The IL-17<sup>+</sup> Ly6G<sup>+</sup> (double-positive) cells were quantified and represented as a percentage of DAPI<sup>+</sup> cells in all four treatment groups. This experiment was performed only once as a single experimental replicate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>IL-17 production inhibition is key to limiting TB severity in WT mice.</title><p>The experimental plan is shown in <xref ref-type="fig" rid="fig5">Figure 5(B)</xref>. C57BL/6 mice were infected with H37Rv at a 100–200 CFU dose via the aerosol route. At 3 weeks post-infection, treatment with celecoxib and SR 2211 (inverse agonist for RORγt) was started for a further 3 weeks. Celecoxib was administered orally once a day, and SR 2211 was administered intraperitoneally thrice a week. At 6 weeks post-infection, mice from the treatment and untreated control groups were sacrificed, and lung and spleen were harvested for CFU, histopathology, and FACS analysis. (<bold>A</bold>) Lung PMN count normalized to 1 million of total acquired cells in the above-stated treatment groups of mice. The statistical significance of the treatment groups was assessed by applying a one-way ANOVA test, n=5 mice/group. (<bold>B</bold>) H&amp;E-stained lung sections showing pathology in SR2211+Celecoxib treatment group. (<bold>C</bold>) Granuloma scoring depicting lung pathology in four treatment groups of mice. n=5 mice per treatment group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-10"><title>Modulating IL-17 via COX2 inhibition or by RORγt inhibition enhances bacterial control in BCG-vaccinated animals by lowering Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic></title><p>Our above data in WT and <italic>ifng<sup>-/-</sup></italic> mice indicate IL-17-producing Ly6G<sup>+</sup>Gra as one of the drivers of TB pathology. We next evaluated whether IL-17 inhibition could also help enhance the efficacy of BCG-mediated control of TB in WT mice. For IL-17 inhibition, we used celecoxib treatment since it effectively reduced the IL-17 levels in the lungs of WT mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). BCG-vaccinated and PBS control WT mice were challenged with H37Rv (100–200 CFU, <xref ref-type="fig" rid="fig6">Figure 6A</xref>) at 8 weeks post-immunization. Celecoxib treatment was started four weeks after the infection, and we collected samples at 8 and 12 weeks p.i. Celecoxib treatment significantly enhanced the efficacy of BCG against <italic>Mtb</italic> challenge, leading to a reduced bacterial burden in the lung of BCG +Celecoxib mice compared to BCG-alone mice at 12 weeks p.i. (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, left panel). BCG +Celecoxib, however, did not show a significant advantage over the BCG-alone group for spleen <italic>Mtb</italic> load (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, right panel). Importantly, the BCG +Celecoxib group also showed significantly reduced <italic>Mtb</italic> burden in lung Ly6G<sup>+</sup>Gra or PMN cells compared to the BCG-alone group (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Celecoxib treatment led to a decline of ~45% in the <italic>Mtb</italic> burden in lung Ly6G<sup>+</sup>Gra (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), which also corresponded to better histopathology (<xref ref-type="fig" rid="fig6">Figure 6D–E</xref>). Similar observations were also made when IL-17 was directly inhibited using SR2211 (<xref ref-type="fig" rid="fig6">Figure 6F–H</xref>). Together, we conclude that the IL-17-Ly6G<sup>+</sup>Gra axis contributes to TB pathology and interferes with the efficacy of the BCG vaccine and, therefore, could be targeted to achieve better control of TB.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Targeting IL-17 via COX2 inhibition and RORγt inhibition augments BCG efficacy by lowering Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic>.</title><p>(<bold>A</bold>) Study plan. C57BL/6 mice were vaccinated intradermally with 10<sup>6</sup> BCG bacilli. After 8 weeks, vaccinated and unvaccinated mice were subjected to aerosol infection with H37Rv (100 CFU). 4 weeks post<italic>-Mtb</italic> infection, mice received celecoxib (50 mg/kg, orally) treatment for 4 and 8 weeks in with and without BCG vaccination group, keeping the untreated arm as control. At 4, 8, and 12 weeks post-infection, mice were euthanized, and lung and spleen were harvested. (<bold>B</bold>) Enumeration of lung and spleen mycobacterial burden in all four treatment groups (control, BCG-vaccinated, celecoxib-treated, and BCG-vaccinated celecoxib-treated) at 8 and 12 weeks post-infection. (<bold>C</bold>) <italic>Mtb</italic> burden in individual sorted cells (PMNs, macrophages, and MSCs), plotted as CFU/10<sup>4</sup> sorted cells at 12 weeks post-infection time point, from the lungs of all four treatment groups of mice. A two-way ANOVA statistical test was applied to compare all four treatment groups at different time points. Sample size (n)=5 mice/group in all treatment groups. (<bold>D</bold>) H&amp;E-stained lung sections of control, BCG-vaccinated, celecoxib-treated, and BCG-vaccinated celecoxib-treated group at ×10 magnification. (<bold>E</bold>) Granuloma scoring of the same treatment groups depicting histopathology. This experiment was independently conducted in three separate experimental replicates (<bold>F</bold>) Study plan. C57BL/6 mice were vaccinated intradermally with 10<sup>6</sup> BCG bacilli. After 8 weeks, vaccinated and unvaccinated mice were subjected to aerosol infection with H37Rv (100 CFU). At 4 weeks post-Mtb infection, mice were administered SR2211 (20 mg/kg) intraperitoneally three times per week for 3 weeks, in both BCG-vaccinated and unvaccinated groups, with untreated mice serving as vehicle control. At 7 weeks post-infection, mice were euthanized, and lung and spleen were harvested. (<bold>G</bold>) The Mtb burden in sorted PMNs was assessed at 7 weeks post-infection and expressed as CFU per 10⁴ sorted cells from the lungs of all four treatment groups (Control, BCG-vaccinated, SR2211-treated, and BCG-vaccinated+SR2211-treated). (<bold>H</bold>) Lung mycobacterial burden was also quantified across all four groups at the same time point. A two-way ANOVA was performed to compare the groups. Sample size (n)=6 mice/group in all treatment groups. This experiment was performed only once as a single experimental replicate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig6-v1.tif"/></fig></sec><sec id="s2-11"><title>The IL-17-Granulocyte axis in human TB subjects</title><p>The results so far establish the role of the IL-17- Ly6G<sup>+</sup>Gra axis in TB pathology in mice. To verify the existence of a similar axis in human TB, we mined data from a prospective cohort study of pulmonary tuberculosis (PTB). This cohort comprised 201 subjects of PTB, who were treated with anti-TB treatment (ATT) regime for 6–8 months and followed up for an additional 1 year to track any recurrence (<xref ref-type="fig" rid="fig7">Figure 7A</xref>; <xref ref-type="bibr" rid="bib50">Kumar et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Kumar et al., 2020</xref>). Among those, 133 subjects showed no recurrence of TB at one year of follow-up and were therefore considered cured of PTB, whereas 68 subjects failed the treatment and showed manifestation of TB recurrence and death (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). We compared blood IL-17 and neutrophil levels at the time of recruitment (under treatment-naïve conditions) among these subjects of the cohort. The failed treatment group had significantly higher serum IL-17 levels and absolute blood neutrophil count at the time of recruitment compared with those who were successfully cured from the disease and showed no recurrence (<xref ref-type="fig" rid="fig7">Figure 7B–C</xref>). Moreover, the treatment failure group also had a significantly higher neutrophil-to-lymphocyte ratio (NLR) at the time of recruitment (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Higher NLR has been demonstrated to be a risk of TB and associated with poor treatment outcomes (<xref ref-type="bibr" rid="bib33">Han et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Miyahara et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Nakao et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Suryana et al., 2022</xref>). Taken together, our data suggests that the IL-17-neutrophil axis influences TB pathogenesis both in mice and humans, thereby providing an opportunity to develop a protective strategy by targeting this axis (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>High IL-17 precipitates adverse treatment outcomes in pulmonary TB patients.</title><p>(<bold>A</bold>) Pulmonary TB (PTB) patients-cohort study design: It includes 133 subjects that were cured of TB after the full standard ATT regime and 68 subjects that have failed the standard ATT regime (independent of drug resistance) or have experienced recurrence of symptoms. At the time of recruitment in the cohort study, the baseline blood levels of IL-17, neutrophils, and total lymphocytes in both the treatment groups were measured. (<bold>B</bold>) Blood IL-17 levels, (<bold>C</bold>) blood neutrophil levels, and (<bold>D</bold>) blood neutrophil/total lymphocyte ratio in treatment failure and treatment success cases of pulmonary TB patients. Unpaired student’s t-test was applied to calculate significance. (<bold>E</bold>) Schematic showing the therapeutic potential of COX-2 and RORγt inhibitor in TB by targeting IL-17-PMN axis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The immune response elicited by <italic>Mtb</italic> infection triggers the recruitment of diverse innate and adaptive immune cells to the site of infection, leading to the formation of granulomas (<xref ref-type="bibr" rid="bib81">Ramakrishnan, 2012</xref>). In the granulomas, <italic>Mtb</italic> coopts these immune cells as its niche and evades adaptive immune response during the chronic phase (<xref ref-type="bibr" rid="bib11">Chandra et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Lovewell et al., 2021</xref>). Different monocyte and macrophage subpopulations in the lungs are reported as major immune cells harboring the intracellular <italic>Mtb</italic> in the lungs of infected mice, which may also impact <italic>Mtb</italic> growth and survival differentially (<xref ref-type="bibr" rid="bib54">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Huang et al., 2018</xref>). Our observation that Ly6G<sup>+</sup>Gra, which typically represents the neutrophil or PMN population, is the major <italic>Mtb</italic>-infected pool in the lungs brings a new dimension to the cellular niches of <italic>Mtb</italic>. Previously, it was reported that the highest number of bacilli is present in the neutrophils early during the infection (<xref ref-type="bibr" rid="bib36">Huang et al., 2018</xref>). Yet another study showed Ly6G<sup>+</sup> granulocytes as a permissive niche to <italic>Mtb</italic> (<xref ref-type="bibr" rid="bib59">Lovewell et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Mishra et al., 2017</xref>). However, so far, no literature suggests that the neutrophil-resident population could be responsible for lower vaccine efficacy. Thus, the inability of BCG vaccination to clear the intracellular <italic>Mtb</italic> burden from Ly6G<sup>+</sup>Gra has serious implications. Both pro- and antibacterial roles are attributed to granulocytes, specifically neutrophils, largely due to heterogeneity in their population (<xref ref-type="bibr" rid="bib55">Leliefeld et al., 2018</xref>; <xref ref-type="bibr" rid="bib97">Tsuda et al., 2004</xref>). While certain innate immune responses of BCG-vaccinated animals are attributed to trained immunity (<xref ref-type="bibr" rid="bib42">Kaufmann et al., 2018</xref>), it is also reported that BCG vaccination results in neutrophil reprogramming, leading to an enhanced antibacterial state (<xref ref-type="bibr" rid="bib69">Moorlag et al., 2020</xref>). We did observe BCG-mediated decline in the Ly6G<sup>+</sup>Gra-resident <italic>Mtb</italic> population, suggesting an antibacterial activation state. However, they continued to represent the largest, if not the only, pool of intracellular bacilli in those animals. Our observations were in line with some human studies, where in TB patients, neutrophils were the most predominant infected phagocytes in the sputum samples, BAL fluid, and lung cavities (<xref ref-type="bibr" rid="bib23">Eum et al., 2010</xref>).</p><p>Granulocyte recruitment to the site of inflammation is driven by chemotactic stimuli like CXCL1, CXCL2, CCL3, etc that trigger neutrophil chemotaxis under resting or activated states via the chemotactic receptor CXCR2 (<xref ref-type="bibr" rid="bib47">Kolaczkowska and Kubes, 2013</xref>) and the eicosanoids downstream to COX2 (<xref ref-type="bibr" rid="bib30">Funk, 2001</xref>; <xref ref-type="bibr" rid="bib56">Lemos et al., 2009</xref>). In the <italic>ifng<sup>-/-</sup></italic> mice, the neutrophil chemotactic signals were upregulated to a varying degree upon <italic>Mtb</italic> infection. In addition, IL-17 is also implicated in neutrophil recruitment across different settings (<xref ref-type="bibr" rid="bib27">Flannigan et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Gelderblom et al., 2012</xref>). In TB, IL-17 from CD4<sup>+</sup> T cells is believed to trigger neutrophil infiltration (<xref ref-type="bibr" rid="bib72">Nandi and Behar, 2011</xref>). Interestingly, IFNγ can block IL-17 production and, therefore, serve as the mechanism for high neutrophilia in <italic>ifng<sup>-/-</sup></italic> mice upon <italic>Mtb</italic> infection (<xref ref-type="bibr" rid="bib72">Nandi and Behar, 2011</xref>). Interestingly, IFNγ can also trigger nonhematopoietic cells in the lung epithelial and endothelial compartments to promote IDO expression, which restrains IL17 production and neutrophil-driven inflammation, thus limiting<italic> Mtb</italic> burden (<xref ref-type="bibr" rid="bib21">Desvignes and Ernst, 2009</xref>). We also observed high Ly6G<sup>+</sup>Gra infiltration and lung IL-17 levels in <italic>Mtb</italic>-infected <italic>ifng<sup>-/-</sup></italic> mice. However, the source of lung IL-17 appeared to be distinct from the typical Th17 cells, consistent with a lack of any increase in IL-23 levels, important for the expansion of Th17 cells (<xref ref-type="bibr" rid="bib32">Haines et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Langrish et al., 2005</xref>; <xref ref-type="bibr" rid="bib93">Teng et al., 2015</xref>). Instead, our results show that Ly6G<sup>+</sup>Gra are a major source of IL-17 in <italic>ifng<sup>-/-</sup></italic> mice as well as in WT mice. Since Ly6G<sup>+</sup>Gra are also known to express IL-17 receptors (<xref ref-type="bibr" rid="bib91">Tan et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Taylor et al., 2014</xref>), these results raise the possibility that IL-17 and Ly6G<sup>+</sup>Gra could establish a self-amplification loop, leading to severe TB pathology.</p><p>Including a COX2 inhibitor in the experiments with WT mice and <italic>ifng<sup>-/-</sup></italic> mice was very insightful. The crosstalk between prostaglandins and IL-17 is reported as they help Th17 cell differentiation (<xref ref-type="bibr" rid="bib73">Napolitani et al., 2009</xref>). The COX2 enzyme competes with the 5-lipoxygenase (5-LO) enzyme for the substrate arachidonic acid to promote prostaglandin and thromboxane biosynthesis, and inhibiting COX2 redirects arachidonate towards the leukotriene pathway (<xref ref-type="bibr" rid="bib30">Funk, 2001</xref>). To note, increased production of leukotriene is also associated with TB protection (<xref ref-type="bibr" rid="bib78">Pavan Kumar et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Peres et al., 2007</xref>; <xref ref-type="bibr" rid="bib95">Tobin et al., 2010</xref>). While COX2 inhibition could not significantly impact IL-17 levels in the <italic>ifng<sup>-/-</sup></italic> mice, it was very effective in controlling IL-17 levels in the WT mice. Combining IL-17 neutralization with COX2 inhibition showed better <italic>Mtb</italic> control in the <italic>ifng<sup>-/-</sup></italic> mice. Inhibiting RORγt with SR2211 provided insights into the crosstalk between IL-17 and COX2 in the WT mice. RORγt is a classic nuclear receptor implicated in the Th17 cell differentiation (<xref ref-type="bibr" rid="bib38">Ivanov et al., 2006</xref>). In the WT mice, while RORγt inhibition or COX2 inhibition alone significantly lowered <italic>Mtb</italic> burden in the lung Ly6G<sup>+</sup>Gra, no synergistic or additive effect on <italic>Mtb</italic> burden was seen upon combined treatment with SR2211 and celecoxib, suggesting that COX2 and IL-17 act in a common pathway. To note, only in the WT and not in the <italic>ifng<sup>-/-</sup></italic> mice, COX2 inhibition completely abrogated lung IL-17 levels, suggesting COX2 largely worked through IL-17 regulation in the <italic>Mtb</italic>-infected WT mice.</p><p>Our observation of Ly6G<sup>+</sup>Gra as a major source of IL-17 during <italic>Mtb</italic> infection in both WT and <italic>ifng<sup>-/-</sup></italic> mice is unprecedented. Granulocytes, specifically neutrophils, are known to express COX2 under inflammatory conditions and secrete PGE2 (<xref ref-type="bibr" rid="bib63">Maloney et al., 1998</xref>). Also, PGE2 can regulate neutrophil migration, specifically when induced by IL-23/IL-17 (<xref ref-type="bibr" rid="bib56">Lemos et al., 2009</xref>). However, we suspect PGE2 also somehow curtails the antibacterial responses of neutrophils since we observed conditions where, without a drop in neutrophil count, the intra-Ly6G<sup>+</sup>Gra bacillary load was reduced significantly upon COX2 inhibition.</p><p>Neutrophils express RORγt and IL-17 and can be activated through autocrine IL-17A-IL-17RC interactions during fungal infections (<xref ref-type="bibr" rid="bib92">Taylor et al., 2014</xref>). However, unlike our results, the IL-17-mediated autocrine activation of neutrophils was shown to elicit strong anti-microbial functions in the neutrophils (<xref ref-type="bibr" rid="bib92">Taylor et al., 2014</xref>). It is possible that microbial species and infection sites could drive these responses differentially. Thus, our results suggest that IL-17-Ly6G<sup>+</sup>Gra crosstalk restrains the protective host responses in normal and highly susceptible models of TB.</p><p>As reported earlier, the Ly6G<sup>+</sup>Gra-resident pool of <italic>Mtb</italic> showed resilience to BCG vaccination. However, COX2 inhibition in the BCG-vaccinated WT mice significantly reduced the bacterial burden and disease pathology. Since SR2211 also worked in a similar way as COX2 in enhancing BCG vaccine efficacy, and under both conditions, IL-17 levels were dramatically reduced in the lung homogenates, the IL-17-mediated mechanism in vaccine efficacy appears plausible. Alternatively, it is reported that BCG-dependent COX-2/PGE2 pathway activation blunts macrophage, DC, and PMN responses (<xref ref-type="bibr" rid="bib3">Ballinger et al., 2006</xref>; <xref ref-type="bibr" rid="bib86">Serezani et al., 2007</xref>; <xref ref-type="bibr" rid="bib87">Sheppe and Edelmann, 2021</xref>). This has led to explorations on a combination of BCG with selective COX2 inhibitors to ameliorate the efficacy of BCG (EP2763666B1; <xref ref-type="bibr" rid="bib37">Ibrahim et al., 2021</xref>). Curiously, selective COX-2 inhibition by celecoxib had no impact on neutrophil numbers in the lungs; it significantly reduced the <italic>Mtb</italic> load in the neutrophils in BCG-vaccinated animals. Thus, our results show that the COX2 pathway contributes to lowering the efficacy of BCG-mediated protection by preventing the antibacterial functions of neutrophils. The COX-2-mediated negative regulation of neutrophil antibacterial response is also shown in the case of <italic>Pseudomonas aeruginosa</italic> infection (<xref ref-type="bibr" rid="bib84">Sadikot et al., 2007</xref>).</p><p>The results on the human cohort re-emphasize the primacy of neutrophils in determining the disease outcome in humans. We found that high neutrophils and IL-17 can predict treatment failure. This underscores a similar neutrophil-IL-17 axis operational in humans underlying disease severity, as observed in the mouse model in this study. Interestingly, a neutrophil-driven transcriptional signature was earlier reported to be associated with active TB (<xref ref-type="bibr" rid="bib6">Berry et al., 2010</xref>). It is noteworthy that high neutrophilia alone has been shown to predict death in TB patients (<xref ref-type="bibr" rid="bib60">Lowe et al., 2013</xref>).</p><p>The results from mice lacking IFNγ have immediate clinical application. A relatively small fraction but a sizable number of TB cases belong to a category known as Mendelian Susceptibility to Tubercular Diseases or MSMD, which typically is caused by a mutation in the IFNγ/IL12p70 pathway (<xref ref-type="bibr" rid="bib26">Filipe-Santos et al., 2006</xref>; <xref ref-type="bibr" rid="bib43">Kerner et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Levin et al., 1995</xref>). These patients develop severe diseases even upon exposure to BCG and respond poorly to anti-TB treatment (<xref ref-type="bibr" rid="bib10">Casanova et al., 1995</xref>; <xref ref-type="bibr" rid="bib62">Mahdaviani et al., 2022</xref>). We believe the MSMD phenotype could be a manifestation of the IL-17-neutrophil axis observed in <italic>ifng<sup>-/-</sup></italic> animals, which could be exploited for better treatment outcomes in these patients.</p><p>One clear limitation of the study is the lack of a detailed characterization of the diverse granulocyte populations in the lungs. For example, experiments in the <italic>ifng<sup>-/-</sup></italic> suggested a potential pathological role of CD11b<sup>mid</sup>Ly6G<sup>hi</sup> granulocytes. The heterogeneity among granulocytes is well reported, and emerging evidence suggests neutrophils are detrimental to the host, while eosinophils are protective to the host against TB (<xref ref-type="bibr" rid="bib65">Mayer-Barber, 2023</xref>). We believe further characterization of this diverse population could provide greater insights into the protective and pathological roles played by granulocytes. Another shortcoming is the lack of direct evidence of IL-17 secretion by PMNs in the lung granulomas, which would potentially require PMN-specific genetic deletion of IL-17.</p><p>Finally, there is a lack of consensus on the protective or pathological role of IL-17 in TB. The protective effect of IL-17 has been shown in the mouse model of TB in the context of vaccination (<xref ref-type="bibr" rid="bib14">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Desel et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Khader et al., 2007</xref>). Ironically, in the majority of such studies, the IL-17 response was measured through ex vivo stimulation of isolated T cells. In contrast, in this study, we measured IL-17 levels in the lung homogenates, which could more accurately capture the function of this cytokine in the TB granulomas in situ.</p><p>To conclude, through this study, we experimentally establish Ly6G<sup>+</sup>Gra as a niche for <italic>Mtb</italic> under normal and severe disease conditions, largely facilitated by IL-17 and the COX2 pathways. Targeted inhibition of IL-17 or COX2 can be exploited to enhance the efficacy of BCG or other vaccine candidates and as adjunct therapeutic strategies for the normal population and among those with genetic vulnerability towards severe TB.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Ethical clearance</title><p>ITB biopsy samples and control samples were obtained from the Department of Pathology, AIIMS, New Delhi. These biopsy samples were taken from the patients for diagnostic purposes after taking their written informed consent. The use of the archived leftover biopsy samples was approved by the institute’s EC of AIIMS (Ref no. IEC-304/02-06-2017), and ICGEB (Ref no. ICGEB/IEC/2017/06-verII and ICGEB/IEC/2016/03) and the same were accessed according to the institutional guidelines. Animal experiments were approved by Institutional Animal Ethics Committee, ICGEB (ICGEB/IAEC/280718 /CI-14), (ICGEB/IAEC/07032020 /CI-18), and (ICGEB/IAEC/18092021 /CI-16). The study on human PTB subjects was approved by the Ethics Committees of the Prof. M. Viswanathan Diabetes Research Center (ECR/51/INST/TN/ 2013/MVDRC/01) and NIRT (NIRT-INo:2014004). Informed written consent was obtained from all participants. All the methods were performed in accordance with the relevant institutional ethical committee guidelines.</p></sec><sec id="s4-2"><title>Reagents and antibodies</title><p>Tween-20 (P1379), Vectashield (F6182), Triton-X-100 (9036-19-5), DNase 1 (D5025), Collagenase D (11088858001), Propidium Iodide (P4170), HBSS (H6648), Trizol (T9424), Hematoxylin (51275), Eosin (318906), Formalin (HT501128), Celecoxib (SML3031-50MG), DAPI (28718-90-3), Xylene (CAS-1330-20-7), Absolute ethanol (CAS- 64-17-5), Sodium Citrate (CAS-–6132-04-3) were obtained from Sigma-Aldrich. SR 2211, Selective RORγt inverse agonist (4869) was procured from TOCRIS. 7H9 (271310), 7H11 (212203), ADC (211887), OADC (211886) FACS Flow Sheath Fluid (342003), Accudrop Fluorescent Beads (345249), CS&amp;T Research Beads Kit (655050), all FACS antibodies used for acquisition and sorting (details are provided in the separate table) were procured from Becton Dickinson Private Limited. Fixable Viability Dye eFluor 780 used for live/dead staining was obtained from eBioscience. InVivoMAb anti-mouse IL-17A (BE0173), InVivoPure pH 7.0 Dilution Buffer (IP0070), InVivoMAb mouse IgG1 isotype control, unknown specificity (BE0083), InVivoPure pH 6.5 Dilution Buffer (IP0065) were purchased from BioXcell. Mouse IL-17A ELISA Kit (ab199081), mouse PGE2 ELISA Kit ab287802 and Cytokine &amp; Chemokine 36-Plex Mouse ProcartaPlexTM Panel 1 A (EPX360-26092-901) for Luminex assay were obtained from Abcam and Thermo Fisher, respectively. Penta antibiotic mix (FD260-5VL) was procured from Himedia. Rabbit polyclonal <italic>Mycobacterium tuberculosis</italic> Ag85B (ab43019) antibody was purchased from Abcam.</p></sec><sec id="s4-3"><title>Mycobacterial cultures</title><p>Bacterial strains: Lab-adapted strain of <italic>Mycobacterium tuberculosis</italic>, H37Rv, seed stock was received from Colorado State University. BCG (Pasteur strain) was obtained from the National Institute of Immunology, New Delhi. For <italic>Mtb</italic> ex vivo and in vivo infection experiments, H37Rv and BCG mycobacterial cultures were grown in 7H9 media (BD Difco) supplemented with 10% Albumin–Dextrose–Catalase (ADC, BD, Difco) and incubated in an orbiter shaker at 100  rpm, 37  °C till the growth reached the log phase. The log phase cultures were pelleted down, and the pellet was resuspended in either saline (for aerosol infection in mice) or culture media (for ex vivo infection in cells). Single-cell suspensions of H37Rv and BCG were prepared by passing bacterial cultures seven times through 23-gauge needles, five times through 26-gauge needles, and three times through 30-gauge needles.</p></sec><sec id="s4-4"><title>Animals</title><p>WT C57BL/6 mice were procured from animal house, ICGEB, New Delhi and <italic>IFNγ<sup>-/-</sup></italic> C57BL/6 mice were procured from animal house, NII, New Delhi. Both male and female, 6–8 weeks old mice were used for all the in vivo experiments. <italic>Mtb</italic>-infected mice were housed in our biosafety level-3 laboratory and kept pathogen-free by routine serological and histopathological examinations. Animal protocols employed in this study were approved by the Institutional Animal Ethics Committee.</p></sec><sec id="s4-5"><title>Aerosol challenge in C57BL/6 mice with H37Rv strain</title><p>All mice experiments were carried out in the Tuberculosis Aerosol Challenge Facility (TACF, ICGEB, New Delhi, India). C57BL/6 mice were housed in cages within a biosafety level 3 laminar flow enclosure. According to the standardized protocol, mice were infected with 100–200 CFU (unless otherwise stated) with H37Rv in a Wisconsin-Madison chamber. To confirm the infection establishment and to enumerate the exact CFU delivered, two animals were selected randomly and humanely euthanized 24 hr post-aerosol challenge. The lung tissues were harvested and homogenized in 1 X PBS, followed by plating on Petri plates containing Middlebrook 7H11 agar (Difco) supplemented with 10% OADC (Becton, Dickinson) 0.5% glycerol. The colonies were counted after 21 days to enumerate the <italic>Mtb</italic> load.</p></sec><sec id="s4-6"><title>Drug treatment and BCG vaccination of mice</title><p>COX-2 inhibitor Celecoxib (50 mg/kg) was administered to the mice through oral gavaging once per day, according to the timeline of the experiment. RORγt inhibitor SR2211 (20 mg/kg) was administered to the mice through the intra-peritoneal route every alternate day according to the timeline of the experiment. Mice were vaccinated with BCG intradermally at a dose of 1 million bacilli per mouse.</p></sec><sec id="s4-7"><title>CFU plating post<italic>-Mtb</italic> infection</title><p>At various time points post<italic>-Mtb</italic> infection, lung and spleen tissues were harvested from the infected mice. The left half lung of the mice was homogenized and serially diluted in 1 X PBS. Different dilutions were plated in duplicates on 7H11 agar plates supplemented with 10% OADC to get <italic>Mtb</italic> colonies within the countable range. Similarly, spleens were also harvested, homogenized, and serially diluted in 1 X PBS, followed by plating on 7H11 agar plates. The colonies were counted after 21 days to enumerate the <italic>Mtb</italic> load.</p></sec><sec id="s4-8"><title>FACS sample preparation</title><p>The right half of the lung of the infected mice was used in the preparation of single-cell suspension followed by FACS sorting and subsequent plating of sorted cells (i.e. neutrophils, macrophages, and mesenchymal stem cells). For sorting, the tissue was washed with 1 X PBS and chopped into small pieces. 20 U/ml DNase 1 and 1 mg/ml collagenase D were added to the chopped tissue and incubated for 30–45 min at 37 °C. After incubation, the chopped lung tissues were passed through the nylon mesh of a 70-µm cell strainer to get a single-cell suspension. The cells were pelleted at 1200 rpm, and the cell pellet was treated with 1 X ACK RBC lysis buffer to get rid of RBCs and washed with 1 X PBS. The cells were incubated with Fc-Block antibody (CD16/32 FCR-γ antibody) on ice for 15 min to inhibit the binding of surface antibodies to Fc receptors on the immune cell surface. The cells were washed with PBS and subsequently stained with the antibody cocktail of CD45.2, CD11b, Ly6G, MHCII, CD64, MerTK, Sca-1, CD90.1, and CD73 and placed on ice for 45 min. Dead cells were stained with fixable viability dye eFluor 780 (FVD eFluor 780) or Propidium Iodide (PI) at 5 µg/ml concentration just before acquisition.</p></sec><sec id="s4-9"><title>FACS cell sorting</title><p>After staining and washing, the lung cells were again passed through a 40 µm strainer before acquisition into the FACS machine to ensure formation of single-cell suspension. The whole sample was acquired to get the maximum number of live sorted cells (neutrophils, macrophages, and mesenchymal stem cells). The sorted cells were then pelleted (at 13,000 RPM), lysed, and plated on 7H11 plates. The colonies were counted after 21 days to enumerate the <italic>Mtb</italic> burden within each sorted cell type.</p></sec><sec id="s4-10"><title>RNA-Seq analysis</title><p>Reads were quality filtered using Trimmomatic (v.0.39, LEADING:10 TRAILING:10 SLIDING WINDOW:4:15 MINLEN:75); (<xref ref-type="bibr" rid="bib7">Bolger et al., 2014</xref>) and were assessed for quality using FastQC (v.10.1; <xref ref-type="bibr" rid="bib2">Andrews, 2010</xref>) and visualized with MultiQC (v.1.9; <xref ref-type="bibr" rid="bib24">Ewels et al., 2016</xref>). Salmon (v.1.8, –numGibbsSamples 30; <xref ref-type="bibr" rid="bib76">Patro et al., 2017</xref>) was used to quantify quality filtered reads against mouse genome (GRCm39, primary assembly) with Gencode annotation (v.M30; <xref ref-type="bibr" rid="bib29">Frankish et al., 2019</xref>). Profiles were imported using tximeta (v.1.10; <xref ref-type="bibr" rid="bib58">Love et al., 2020</xref>) and SummarizedExperiment (v.1.22; <xref ref-type="bibr" rid="bib70">Morgan et al., 2018</xref>) which were then summarized to gene-level expression. The following biotypes were filtered out: pseudogenes, TEC, snRNA, lncRNA, miRNA, snoRNA, misc_RNA, rRNA, ribozyme, scaRNA, sRNA, scRNA, Mt_tRNA, Mt_rRNA. The dataset was further filtered to remove features not expressed across the whole dataset. The dataset was normalized to scaled TPM values. Downstream analyses are described in the statistical analyses section.</p></sec><sec id="s4-11"><title>Multiplex microbead-based immunoassay (Luminex)</title><p>Mouse lung homogenates were collected for Luminex analysis using the Cytokine &amp; Chemokine 36-Plex Mouse ProcartaPlexTM Panel 1 A (Thermo Fisher, # EPX360-26092-901). Samples were incubated with fluorescent-coded magnetic beads pre-coated with respective antibodies in a black 96-well clear-bottom plate overnight at 4 °C. After incubation, plates were washed five times with wash buffer (PBS with 1% BSA (Capricorn Scientific) and 0.05% Tween-20 (Promega)). Sample antibody-bead complexes were incubated with biotinylated detection antibodies for 1 hr and washed five times. Subsequently, Streptavidin-PE was added and incubated for another 30 min. Plates were washed five times before sample-antibody-bead complexes were resuspended in sheath fluid for acquisition on the FLEXMAP 3D (Luminex) using xPONENT 4.0 (Luminex) software. Data analysis was done using Bio-Plex ManagerTM 6.1.1 (Bio-Rad). Standard curves were generated with a 5-PL (5-parameter logistic) algorithm, reporting values for both mean fluorescence intensity (MFI) and concentration data.</p></sec><sec id="s4-12"><title>Tissue immunofluorescence assay (IFA)</title><p>Five-micron thick sections of paraffin-embedded tissue sections were taken in poly-L-lysine-coated slide. Deparaffinization was performed by heating the slides at 50 °C for 20 s till the wax melts, followed by the subsequent steps, 100% xylene for 10 min, xylene and absolute ethanol for 10 min, 100% ethanol for 10 min, 70% ethanol for 5 min, 50% ethanol, distilled water for 5 min, and a final wash in 1 x PBS for 5 min. Antigen retrieval was performed in antigen retrieval buffer (10 mM Sodium Citrate, 0.05% tween-20, pH: 6) by heating the slides at 100 °C for 15 min. After antigen retrieval, permeabilization was performed with 0.04% Triton-X 100 in 1 X PBS (0.04% PBST) for 20 min followed by proper washing with 1 X PBS. Blocking was done by 3% BSA for 1 hr. Sequential addition of primary antibody was performed at 1:100 dilution at 4 °C overnight. Primary antibody was washed with 1 X PBS followed by counterstain with DAPI nuclear stain at 1 µg/ml concentration. Mounting was done with a drop of Vectashield.</p></sec><sec id="s4-13"><title>Histopathological studies</title><p>Formalin-fixed tissue samples (&lt;5 mm thick) were washed under running water for 4–12 hr. Tissue dehydration was performed in ascending grades of alcohol (30%, 50%, 70%, 90%, 95%) followed by two washes in absolute alcohol, 1 hr each and two washes in xylene for 1 hr each. Paraffinization in melted paraffin wax (57–60<sup>o</sup>C) was performed three times sequentially for 1 hr each. FFPE (formalin-fixed paraffin-embedded) tissue blocks were prepared by placing tissue and melted paraffin in steel molds. Five-µm-thick sections of tissue were cut with the help of a microtome. Tissue sections were allowed to float on a water bath (45–50°C) and placed on a clean glass slide. Deparaffinization was performed by three sequential washes in xylene for 5 min each followed by hydration in descending grades of alcohol (absolute alcohol, 90% and 70%) followed by one wash in water, 5 min each. For H&amp;E staining, slides were first stained with hematoxylin (it stains the nucleus blue) for 5–10 min followed by one wash with water. The slides were subsequently stained with Eosin (it stains the cytoplasm pink) for 5–10 min followed by one wash with absolute alcohol and one wash with xylene. Slides were mounted with coverslips followed by sealing with DPX. Images were acquired on Zeiss microscope.</p></sec><sec id="s4-14"><title>In vivo IL-17 neutralization experiment</title><p>IFNγ knockout C57BL/6 mice were challenged with 100–200 CFU with H37Rv via the aerosol route (as described previously). The anti-mouse IL-17 monoclonal Ab was administered via the intra-peritoneal route at a dose of 100 mg/mouse every 3–4 days starting one day before <italic>M. tuberculosis</italic> infection for the duration of the study, that is 6 weeks. Control groups received matched IgG isotypes. Six weeks post<italic>-Mtb</italic> infection, mice were treated with 50 mg/kg celecoxib through oral route for the duration of the experiments. Mice in all experimental groups were sacrificed at 6 weeks post-infection, according to the experimental timeline. The left half of the lungs and whole spleen of the mice were homogenized and serially diluted in 1 X PBS. Different dilutions were plated in duplicates on 7H11 agar plates and the colonies were counted after 21 days to enumerate the <italic>Mtb</italic> load. The middle lobe of the right lung was preserved in formalin for histopathology and IFA studies. The rest part of the right half lung of the infected mice was used in the preparation of single-cell suspension. The single-cell suspension was divided into two parts and stained with different antibody cocktails. One part was used for FACS sorting and subsequent plating of sorted cells (i.e. neutrophils, macrophages, and mesenchymal stem cells), and the other half was used for FACS acquisition to enumerate Th17 cells inside the lungs. Sera was also collected to quantify IL-17 levels.</p></sec><sec id="s4-15"><title>IL-17/PGE2 ELISA</title><p>IL-17 levels and PGE2 levels in the lung homogenates of uninfected mice, <italic>Mtb</italic>-infected mice, <italic>Mtb</italic>-infected treated mice from various experimental groups were measured using ELISA kits procured from Abcam using the manufacturer’s protocol.</p></sec><sec id="s4-16"><title>Study population (PTB subjects)</title><p>Participants were enrolled from the Effect of Diabetes on Tuberculosis Severity (EDOTS) study, a prospective cohort study conducted in Chennai, India. A total of 68 had unfavorable treatment outcomes, comprising treatment failure, relapse, or death. Inclusion criterion was new smear and culture-positive adults (age 18–75 years). Exclusion criteria were previous treatment for TB, drug-resistant TB, HIV positivity or taking immunosuppressive drugs, and &gt;7 days of anti-TB treatment prior to enrollment. As part of our study protocol, HIV screening was done for all the study participants. The diagnosis of PTB was established by positive sputum culture on solid media with compatible chest X-ray. Anti-TB treatment (ATT) was provided by government TB clinics according to the Revised National Tuberculosis Control Programme standards in effect at that time. Participants were followed up monthly through the 6 months course of treatment and every three months thereafter till 1 year after treatment completion. Cure was defined as negative sputum cultures at months 5 and 6 of treatment.</p><p>Adverse treatment outcomes included treatment failure defined as positive sputum culture at months 5 or 6, all-cause mortality over the duration of treatment, or recurrent TB demonstrated by positive sputum smear and culture with compatible symptoms or chest X-ray within twelve months after initial cure. There was a total of 18 TB treatment failures, 16 deaths, and 34 TB recurrences. Case-control matching was based on age, gender, body mass index (BMI), and diabetic status. Peripheral blood was collected in heparinized tubes. Following centrifugation, plasma was collected and stored at –80 °C till further analysis. Baseline sample collection was performed at enrollment. The demographic and epidemiological data for this cohort have been previously reported (<xref ref-type="bibr" rid="bib50">Kumar et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Kumar et al., 2020</xref>).</p></sec><sec id="s4-17"><title>Human PTB multiplex assay</title><p>Circulating plasma levels of cytokines and chemokines in PTB patients were measured using the Luminex MAGPIX Multiplex Assay system (Bio-Rad, Hercules, CA). Luminex Human Magnetic Assay Kit 45 Plex (R&amp;D Systems) was used to measure the cytokines and chemokine levels according to the manufacturer’s protocol.</p></sec><sec id="s4-18"><title>Statistical analysis-RNAseq data</title><p>Transcriptomics analyses were done in R statistical software environment (v.4.1; <xref ref-type="bibr" rid="bib82">R Development Core Team, 2021</xref>). Statistical analysis was done using swish methodology from fishpond (v.1.8; <xref ref-type="bibr" rid="bib98">Zhu et al., 2019</xref>) and significantly differentially expressed genes (DEGs) were defined based on qvalue ≤0.1 and absolute log<sub>2</sub> fold change ≥1. Enrichment analyses of the significant DEGs were done using gene set co-regulation analysis (geseca) from the fgsea (v1.18) R library (<xref ref-type="bibr" rid="bib48">Korotkevich et al., 2021</xref>) and Gene Ontology (GO) Biological Processes (BP) and KEGG pathways from msigdbr database (v7.5.1). The significance of enrichment is defined by p.value≤0.05. A heatmap of the Luminex cytokine profile was generated with pheatmap (v.1.0.12) using mean z-scaled values and clustered based on Euclidean distance and Ward.D2 methodology.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Software, Investigation, Visualization</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Methodology</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Data curation, Software, Methodology</p></fn><fn fn-type="con" id="con14"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con15"><p>Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con16"><p>Data curation</p></fn><fn fn-type="con" id="con17"><p>Data curation</p></fn><fn fn-type="con" id="con18"><p>Formal analysis</p></fn><fn fn-type="con" id="con19"><p>Data curation</p></fn><fn fn-type="con" id="con20"><p>Resources, Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con21"><p>Resources, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>ITB biopsy samples and control samples were obtained from the Department of Pathology, AIIMS, New Delhi. These biopsy samples were taken from the patients for diagnostic purposes after taking their written informed consent. The use of the archived leftover biopsy samples was approved by the institute's EC of AIIMS (Ref no. IEC-304/02-06-2017), and ICGEB (Ref no. ICGEB/IEC/2017/06-verII and ICGEB/IEC/2016/03) and the same were accessed according to the institutional guidelines.The study on human PTB subjects was approved by the Ethics Committees of the Prof. M. Viswanathan Diabetes Research Center (ECR/51/INST/TN/ 2013/MVDRC/01) and NIRT (NIRT-INo:2014004). Informed written consent was obtained from all participants.</p></fn><fn fn-type="other"><p>Animal experiments were approved by Institutional Animal Ethics Committee, ICGEB (ICGEB/IAEC/280718/CI-14), (ICGEB/IAEC/07032020/CI-18), and (ICGEB/IAEC/18092021/CI-16).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Differentially expressed genes (DEGs) in PMNs identified between each pairwise comparison.</title></caption><media xlink:href="elife-100966-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Differentially regulated genes in Ly6G<sup>+</sup>Gra from unvaccinated, uninfected versus BCG-vaccinated, uninfected animals.</title></caption><media xlink:href="elife-100966-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Gene-set co-regulation analysis of the DEGs with GO-BP in PMNs among the Uninfected control group, <italic>Mtb</italic>-infected group, and BCG-vaccinated <italic>Mtb</italic>-infected group.</title></caption><media xlink:href="elife-100966-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Gene-set co-regulation analysis of the DEGs with KEGG pathways in PMNs among the Uninfected control group, <italic>Mtb</italic>-infected group, and BCG-vaccinated <italic>Mtb</italic>-infected group.</title></caption><media xlink:href="elife-100966-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100966-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The raw RNAseq data used for this study is available at the GEO database with the accession number: GSE238265.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Singhal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>An IL-17-Ly6G+Polymorphonuclear Neutrophil (PMN) axis limits protective host responses against tuberculosis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE238265">GSE238265</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Tuberculosis Aerosol Challenge Facility (TACF), supported by the Department of Biotechnology, Govt of India, for supporting the BSL3 facility. We thank the staff of the Department of Clinical Research and the Department of Bacteriology, NIRT, for valuable assistance in bacterial cultures and radiology and the staff of Prof. M Viswanathan Diabetes Research Center, RNTCP and Chennai corporation for valuable assistance in recruiting the patients for this study. Data in this manuscript were collected as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium. The work on this project was supported by Department of Biotechnology (BT/IC-06/003/91-Flagship program to DK), MDR-TB project from Department of Biotechnology (BT/PR23092/NER/95/589/2017, DK) and SR-National Bioscience Award from Department of Biotechnology (BT/HRD/NBA-NWB/39/2020-21 (4), DK). The research in the DK lab is also supported by the DBT-Wellcome Trust India Alliance Senior Fellowship (IA/S/17/1/503071) and extramural research grants from SERB (EMR/2016/005296 to DK). Priya Sharma is a recipient of a fellowship from the Indian Council of Medical Research (3/1/3/JRF-2017/HRD-LS/55193/79). Raman Deep Sharma is a recipient of a fellowship from the Department of Biotechnology (DBT/JRF/BET-18/I/2018/AL/160).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Sutherland</surname><given-names>TE</given-names></name><name><surname>Rückerl</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-17 and neutrophils: unexpected players in the type 2 immune response</article-title><source>Current Opinion in Immunology</source><volume>34</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2015.03.001</pub-id><pub-id pub-id-type="pmid">25794823</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>FastQC: a quality control tool for high throughput sequence data</data-title><version designator="Version 0.10.1">Version 0.10.1</version><source>GPLv3</source><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballinger</surname><given-names>MN</given-names></name><name><surname>Aronoff</surname><given-names>DM</given-names></name><name><surname>McMillan</surname><given-names>TR</given-names></name><name><surname>Cooke</surname><given-names>KR</given-names></name><name><surname>Olkiewicz</surname><given-names>K</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name><name><surname>Peters-Golden</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation</article-title><source>Journal of Immunology</source><volume>177</volume><fpage>5499</fpage><lpage>5508</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.8.5499</pub-id><pub-id pub-id-type="pmid">17015736</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>CE</given-names></name><name><surname>Boshoff</surname><given-names>HI</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>Dick</surname><given-names>T</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Young</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</article-title><source>Nature Reviews. Microbiology</source><volume>7</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2236</pub-id><pub-id pub-id-type="pmid">19855401</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>JI</given-names></name><name><surname>Geffner</surname><given-names>LJ</given-names></name><name><surname>Romero</surname><given-names>MM</given-names></name><name><surname>Balboa</surname><given-names>L</given-names></name><name><surname>Sabio Y García</surname><given-names>C</given-names></name><name><surname>Ritacco</surname><given-names>V</given-names></name><name><surname>García</surname><given-names>A</given-names></name><name><surname>Cuffré</surname><given-names>M</given-names></name><name><surname>Abbate</surname><given-names>E</given-names></name><name><surname>López</surname><given-names>B</given-names></name><name><surname>Barrera</surname><given-names>L</given-names></name><name><surname>Ambroggi</surname><given-names>M</given-names></name><name><surname>Alemán</surname><given-names>M</given-names></name><name><surname>Sasiain</surname><given-names>MC</given-names></name><name><surname>de la Barrera</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Outbreaks of <italic>Mycobacterium tuberculosis</italic> MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load</article-title><source>The Journal of Infectious Diseases</source><volume>204</volume><fpage>1054</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir460</pub-id><pub-id pub-id-type="pmid">21881121</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MPR</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SAA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Quinn</surname><given-names>C</given-names></name><name><surname>Blankenship</surname><given-names>D</given-names></name><name><surname>Dhawan</surname><given-names>R</given-names></name><name><surname>Cush</surname><given-names>JJ</given-names></name><name><surname>Mejias</surname><given-names>A</given-names></name><name><surname>Ramilo</surname><given-names>O</given-names></name><name><surname>Kon</surname><given-names>OM</given-names></name><name><surname>Pascual</surname><given-names>V</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Chaussabel</surname><given-names>D</given-names></name><name><surname>O’Garra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><volume>466</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id><pub-id pub-id-type="pmid">20725040</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazier</surname><given-names>B</given-names></name><name><surname>McShane</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Towards new TB vaccines</article-title><source>Seminars in Immunopathology</source><volume>42</volume><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1007/s00281-020-00794-0</pub-id><pub-id pub-id-type="pmid">32189035</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadena</surname><given-names>AM</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Heterogeneity in tuberculosis</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.69</pub-id><pub-id pub-id-type="pmid">28736436</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Lamhamedi</surname><given-names>S</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Immunological conditions of children with BCG disseminated infection</article-title><source>Lancet</source><volume>346</volume><elocation-id>581</elocation-id><pub-id pub-id-type="doi">10.1016/s0140-6736(95)91421-8</pub-id><pub-id pub-id-type="pmid">7658805</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Grigsby</surname><given-names>SJ</given-names></name><name><surname>Philips</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Immune evasion and provocation by <italic>Mycobacterium tuberculosis</italic></article-title><source>Nature Reviews. Microbiology</source><volume>20</volume><fpage>750</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00763-4</pub-id><pub-id pub-id-type="pmid">35879556</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaves Torres</surname><given-names>NM</given-names></name><name><surname>Quijano Rodríguez</surname><given-names>JJ</given-names></name><name><surname>Porras Andrade</surname><given-names>PS</given-names></name><name><surname>Arriaga</surname><given-names>MB</given-names></name><name><surname>Netto</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0226507</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0226507</pub-id><pub-id pub-id-type="pmid">31881023</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chizzolini</surname><given-names>C</given-names></name><name><surname>Chicheportiche</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>M</given-names></name><name><surname>de Rham</surname><given-names>C</given-names></name><name><surname>Roux-Lombard</surname><given-names>P</given-names></name><name><surname>Ferrari-Lacraz</surname><given-names>S</given-names></name><name><surname>Dayer</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion</article-title><source>Blood</source><volume>112</volume><fpage>3696</fpage><lpage>3703</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-05-155408</pub-id><pub-id pub-id-type="pmid">18698005</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HG</given-names></name><name><surname>Kwon</surname><given-names>KW</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Back</surname><given-names>YW</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Choi</surname><given-names>E</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antigen-Specific IFN-γ/IL-17-Co-Producing CD4<sup>+</sup> T-Cells are the determinants for protective efficacy of tuberculosis subunit vaccine</article-title><source>Vaccines</source><volume>8</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020300</pub-id><pub-id pub-id-type="pmid">32545304</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Griffin</surname><given-names>JP</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name><name><surname>Orme</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Disseminated tuberculosis in interferon gamma gene-disrupted mice</article-title><source>The Journal of Experimental Medicine</source><volume>178</volume><fpage>2243</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1084/jem.178.6.2243</pub-id><pub-id pub-id-type="pmid">8245795</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>A</given-names></name><name><surname>Fraga</surname><given-names>AG</given-names></name><name><surname>Fountain</surname><given-names>JJ</given-names></name><name><surname>Rangel-Moreno</surname><given-names>J</given-names></name><name><surname>Torrado</surname><given-names>E</given-names></name><name><surname>Saraiva</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>DR</given-names></name><name><surname>Randall</surname><given-names>TD</given-names></name><name><surname>Pedrosa</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Castro</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with <italic>Mycobacterium tuberculosis</italic></article-title><source>The Journal of Experimental Medicine</source><volume>207</volume><fpage>1609</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1084/jem.20100265</pub-id><pub-id pub-id-type="pmid">20624887</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallenga</surname><given-names>T</given-names></name><name><surname>Schaible</surname><given-names>UE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neutrophils in tuberculosis--first line of defence or booster of disease and targets for host-directed therapy?</article-title><source>Pathogens and Disease</source><volume>74</volume><elocation-id>ftw012</elocation-id><pub-id pub-id-type="doi">10.1093/femspd/ftw012</pub-id><pub-id pub-id-type="pmid">26903072</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dartois</surname><given-names>VA</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Anti-tuberculosis treatment strategies and drug development: challenges and priorities</article-title><source>Nature Reviews. Microbiology</source><volume>20</volume><fpage>685</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00731-y</pub-id><pub-id pub-id-type="pmid">35478222</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Kashino</surname><given-names>SS</given-names></name><name><surname>Pulu</surname><given-names>I</given-names></name><name><surname>Kalita</surname><given-names>D</given-names></name><name><surname>Swami</surname><given-names>V</given-names></name><name><surname>Yeger</surname><given-names>H</given-names></name><name><surname>Felsher</surname><given-names>DW</given-names></name><name><surname>Campos-Neto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant <italic>Mycobacterium tuberculosis</italic></article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>170ra13</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3004912</pub-id><pub-id pub-id-type="pmid">23363977</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desel</surname><given-names>C</given-names></name><name><surname>Dorhoi</surname><given-names>A</given-names></name><name><surname>Bandermann</surname><given-names>S</given-names></name><name><surname>Grode</surname><given-names>L</given-names></name><name><surname>Eisele</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses</article-title><source>The Journal of Infectious Diseases</source><volume>204</volume><fpage>1573</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir592</pub-id><pub-id pub-id-type="pmid">21933877</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvignes</surname><given-names>L</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to <italic>Mycobacterium tuberculosis</italic></article-title><source>Immunity</source><volume>31</volume><fpage>974</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.10.007</pub-id><pub-id pub-id-type="pmid">20064452</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingo-Gonzalez</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Griffiths</surname><given-names>KL</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Bambouskova</surname><given-names>M</given-names></name><name><surname>Gopal</surname><given-names>R</given-names></name><name><surname>Gondi</surname><given-names>S</given-names></name><name><surname>Muñoz-Torrico</surname><given-names>M</given-names></name><name><surname>Salazar-Lezama</surname><given-names>MA</given-names></name><name><surname>Cruz-Lagunas</surname><given-names>A</given-names></name><name><surname>Jiménez-Álvarez</surname><given-names>L</given-names></name><name><surname>Ramirez-Martinez</surname><given-names>G</given-names></name><name><surname>Espinosa-Soto</surname><given-names>R</given-names></name><name><surname>Sultana</surname><given-names>T</given-names></name><name><surname>Lyons-Weiler</surname><given-names>J</given-names></name><name><surname>Reinhart</surname><given-names>TA</given-names></name><name><surname>Arcos</surname><given-names>J</given-names></name><name><surname>de la Luz Garcia-Hernandez</surname><given-names>M</given-names></name><name><surname>Mastrangelo</surname><given-names>MA</given-names></name><name><surname>Al-Hammadi</surname><given-names>N</given-names></name><name><surname>Townsend</surname><given-names>R</given-names></name><name><surname>Balada-Llasat</surname><given-names>J-M</given-names></name><name><surname>Torrelles</surname><given-names>JB</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Horne</surname><given-names>W</given-names></name><name><surname>Kolls</surname><given-names>JK</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Rangel-Moreno</surname><given-names>J</given-names></name><name><surname>Zúñiga</surname><given-names>J</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis</article-title><source>JCI Insight</source><volume>2</volume><elocation-id>e92973</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.92973</pub-id><pub-id pub-id-type="pmid">28978810</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eum</surname><given-names>SY</given-names></name><name><surname>Kong</surname><given-names>JH</given-names></name><name><surname>Hong</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>SN</given-names></name><name><surname>Via</surname><given-names>LE</given-names></name><name><surname>Barry</surname><given-names>CE</given-names><suffix>III</suffix></name></person-group><year iso-8601-date="2010">2010</year><article-title>Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB</article-title><source>Chest</source><volume>137</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1378/chest.09-0903</pub-id><pub-id pub-id-type="pmid">19749004</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewels</surname><given-names>P</given-names></name><name><surname>Magnusson</surname><given-names>M</given-names></name><name><surname>Lundin</surname><given-names>S</given-names></name><name><surname>Käller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MultiQC: summarize analysis results for multiple tools and samples in a single report</article-title><source>Bioinformatics</source><volume>32</volume><fpage>3047</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw354</pub-id><pub-id pub-id-type="pmid">27312411</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatima</surname><given-names>S</given-names></name><name><surname>Kamble</surname><given-names>SS</given-names></name><name><surname>Dwivedi</surname><given-names>VP</given-names></name><name><surname>Bhattacharya</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Ranganathan</surname><given-names>A</given-names></name><name><surname>Van Kaer</surname><given-names>L</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title><italic>Mycobacterium tuberculosis</italic> programs mesenchymal stem cells to establish dormancy and persistence</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>655</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1172/JCI128043</pub-id><pub-id pub-id-type="pmid">31647784</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipe-Santos</surname><given-names>O</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Chapgier</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>G</given-names></name><name><surname>de Beaucoudrey</surname><given-names>L</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Fieschi</surname><given-names>C</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features</article-title><source>Seminars in Immunology</source><volume>18</volume><fpage>347</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2006.07.010</pub-id><pub-id pub-id-type="pmid">16997570</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannigan</surname><given-names>KL</given-names></name><name><surname>Ngo</surname><given-names>VL</given-names></name><name><surname>Geem</surname><given-names>D</given-names></name><name><surname>Harusato</surname><given-names>A</given-names></name><name><surname>Hirota</surname><given-names>SA</given-names></name><name><surname>Parkos</surname><given-names>CA</given-names></name><name><surname>Lukacs</surname><given-names>NW</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name><name><surname>Gaboriau-Routhiau</surname><given-names>V</given-names></name><name><surname>Cerf-Bensussan</surname><given-names>N</given-names></name><name><surname>Gewirtz</surname><given-names>AT</given-names></name><name><surname>Denning</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteria</article-title><source>Mucosal Immunology</source><volume>10</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.80</pub-id><pub-id pub-id-type="pmid">27624780</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>An essential role for interferon gamma in resistance to <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>The Journal of Experimental Medicine</source><volume>178</volume><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id><pub-id pub-id-type="pmid">7504064</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>A-M</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Jungreis</surname><given-names>I</given-names></name><name><surname>Loveland</surname><given-names>J</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Sisu</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Carbonell Sala</surname><given-names>S</given-names></name><name><surname>Chrast</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Di Domenico</surname><given-names>T</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>García Girón</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Izuogu</surname><given-names>OG</given-names></name><name><surname>Lagarde</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Martínez</surname><given-names>L</given-names></name><name><surname>Mohanan</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>P</given-names></name><name><surname>Navarro</surname><given-names>FCP</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Pei</surname><given-names>B</given-names></name><name><surname>Pozo</surname><given-names>F</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Stapleton</surname><given-names>E</given-names></name><name><surname>Suner</surname><given-names>M-M</given-names></name><name><surname>Sycheva</surname><given-names>I</given-names></name><name><surname>Uszczynska-Ratajczak</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Zerbino</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Aken</surname><given-names>B</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJP</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GENCODE reference annotation for the human and mouse genomes</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D766</fpage><lpage>D773</lpage><pub-id pub-id-type="doi">10.1093/nar/gky955</pub-id><pub-id pub-id-type="pmid">30357393</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Prostaglandins and leukotrienes: advances in eicosanoid biology</article-title><source>Science</source><volume>294</volume><fpage>1871</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1126/science.294.5548.1871</pub-id><pub-id pub-id-type="pmid">11729303</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelderblom</surname><given-names>M</given-names></name><name><surname>Weymar</surname><given-names>A</given-names></name><name><surname>Bernreuther</surname><given-names>C</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Arunachalam</surname><given-names>P</given-names></name><name><surname>Steinbach</surname><given-names>K</given-names></name><name><surname>Orthey</surname><given-names>E</given-names></name><name><surname>Arumugam</surname><given-names>TV</given-names></name><name><surname>Leypoldt</surname><given-names>F</given-names></name><name><surname>Simova</surname><given-names>O</given-names></name><name><surname>Thom</surname><given-names>V</given-names></name><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Prinz</surname><given-names>I</given-names></name><name><surname>Hölscher</surname><given-names>C</given-names></name><name><surname>Glatzel</surname><given-names>M</given-names></name><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Gerloff</surname><given-names>C</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Magnus</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke</article-title><source>Blood</source><volume>120</volume><fpage>3793</fpage><lpage>3802</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-412726</pub-id><pub-id pub-id-type="pmid">22976954</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Joyce-Shaikh</surname><given-names>B</given-names></name><name><surname>Porth</surname><given-names>K</given-names></name><name><surname>Boniface</surname><given-names>K</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Basham</surname><given-names>B</given-names></name><name><surname>Anderton</surname><given-names>SM</given-names></name><name><surname>McClanahan</surname><given-names>TK</given-names></name><name><surname>Sadekova</surname><given-names>S</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>McGeachy</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23</article-title><source>Cell Reports</source><volume>3</volume><fpage>1378</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.03.035</pub-id><pub-id pub-id-type="pmid">23623497</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Sim</surname><given-names>YS</given-names></name><name><surname>Ryu</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Shim</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High blood neutrophil-lymphocyte ratio associated with poor outcomes in miliary tuberculosis</article-title><source>Journal of Thoracic Disease</source><volume>10</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.21037/jtd.2017.12.65</pub-id><pub-id pub-id-type="pmid">29600065</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>JB</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>LeBlanc</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Le Lay</surname><given-names>J</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Montminy</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The CREB/CRTC2 pathway modulates autoimmune disease by promoting Th17 differentiation</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7216</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8216</pub-id><pub-id pub-id-type="pmid">26031354</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyckendorf</surname><given-names>J</given-names></name><name><surname>Marwitz</surname><given-names>S</given-names></name><name><surname>Reimann</surname><given-names>M</given-names></name><name><surname>Avsar</surname><given-names>K</given-names></name><name><surname>DiNardo</surname><given-names>AR</given-names></name><name><surname>Günther</surname><given-names>G</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name><name><surname>Ibraim</surname><given-names>E</given-names></name><name><surname>Kalsdorf</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Kontsevaya</surname><given-names>I</given-names></name><name><surname>van Leth</surname><given-names>F</given-names></name><name><surname>Mandalakas</surname><given-names>AM</given-names></name><name><surname>Maurer</surname><given-names>FP</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Nitschkowski</surname><given-names>D</given-names></name><name><surname>Olaru</surname><given-names>ID</given-names></name><name><surname>Popa</surname><given-names>C</given-names></name><name><surname>Rachow</surname><given-names>A</given-names></name><name><surname>Rolling</surname><given-names>T</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Salzer</surname><given-names>HJF</given-names></name><name><surname>Sanchez-Carballo</surname><given-names>P</given-names></name><name><surname>Schuhmann</surname><given-names>M</given-names></name><name><surname>Schaub</surname><given-names>D</given-names></name><name><surname>Spinu</surname><given-names>V</given-names></name><name><surname>Suárez</surname><given-names>I</given-names></name><name><surname>Terhalle</surname><given-names>E</given-names></name><name><surname>Unnewehr</surname><given-names>M</given-names></name><name><surname>Weiner</surname><given-names>J</given-names></name><name><surname>Goldmann</surname><given-names>T</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model</article-title><source>The European Respiratory Journal</source><volume>58</volume><elocation-id>2003492</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.03492-2020</pub-id><pub-id pub-id-type="pmid">33574078</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Nazarova</surname><given-names>EV</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Growth of <italic>Mycobacterium tuberculosis</italic> in vivo segregates with host macrophage metabolism and ontogeny</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>1135</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1084/jem.20172020</pub-id><pub-id pub-id-type="pmid">29500179</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>OM</given-names></name><name><surname>Basse</surname><given-names>PH</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Guru</surname><given-names>K</given-names></name><name><surname>Chatta</surname><given-names>G</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NFκB-Activated COX2/PGE<sub>2</sub>/EP4 axis controls the magnitude and selectivity of BCG-induced inflammation in human bladder cancer tissues</article-title><source>Cancers</source><volume>13</volume><elocation-id>1323</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13061323</pub-id><pub-id pub-id-type="pmid">33809455</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>II</given-names></name><name><surname>McKenzie</surname><given-names>BS</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tadokoro</surname><given-names>CE</given-names></name><name><surname>Lepelley</surname><given-names>A</given-names></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells</article-title><source>Cell</source><volume>126</volume><fpage>1121</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.07.035</pub-id><pub-id pub-id-type="pmid">16990136</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>N</given-names></name><name><surname>Kalam</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Kedia</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Ahuja</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to <italic>Mycobacterium tuberculosis</italic></article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3062</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16877-3</pub-id><pub-id pub-id-type="pmid">32546788</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>BG</given-names></name><name><surname>Samten</surname><given-names>B</given-names></name><name><surname>Dean</surname><given-names>K</given-names></name><name><surname>Wallace</surname><given-names>RJ</given-names></name><name><surname>Brown-Elliott</surname><given-names>BA</given-names></name><name><surname>Tucker</surname><given-names>T</given-names></name><name><surname>Idell</surname><given-names>S</given-names></name><name><surname>Philley</surname><given-names>JV</given-names></name><name><surname>Vankayalapati</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Early IL-17A production helps establish Mycobacterium intracellulare infection in mice</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010454</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010454</pub-id><pub-id pub-id-type="pmid">35363832</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurado</surname><given-names>JO</given-names></name><name><surname>Pasquinelli</surname><given-names>V</given-names></name><name><surname>Alvarez</surname><given-names>IB</given-names></name><name><surname>Peña</surname><given-names>D</given-names></name><name><surname>Rovetta</surname><given-names>AI</given-names></name><name><surname>Tateosian</surname><given-names>NL</given-names></name><name><surname>Romeo</surname><given-names>HE</given-names></name><name><surname>Musella</surname><given-names>RM</given-names></name><name><surname>Palmero</surname><given-names>D</given-names></name><name><surname>Chuluyán</surname><given-names>HE</given-names></name><name><surname>García</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease</article-title><source>Journal of Leukocyte Biology</source><volume>91</volume><fpage>991</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1189/jlb.1211619</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mendonça</surname><given-names>LE</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><name><surname>Tzelepis</surname><given-names>F</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Dumaine</surname><given-names>A</given-names></name><name><surname>Grenier</surname><given-names>JC</given-names></name><name><surname>Mailhot-Léonard</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Belle</surname><given-names>J</given-names></name><name><surname>Besla</surname><given-names>R</given-names></name><name><surname>Mazer</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Nijnik</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><volume>172</volume><fpage>176</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerner</surname><given-names>G</given-names></name><name><surname>Rosain</surname><given-names>J</given-names></name><name><surname>Guérin</surname><given-names>A</given-names></name><name><surname>Al-Khabaz</surname><given-names>A</given-names></name><name><surname>Oleaga-Quintas</surname><given-names>C</given-names></name><name><surname>Rapaport</surname><given-names>F</given-names></name><name><surname>Massaad</surname><given-names>MJ</given-names></name><name><surname>Ding</surname><given-names>J-Y</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Ali</surname><given-names>FA</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Deswarte</surname><given-names>C</given-names></name><name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name><name><surname>Jeanne-Julien</surname><given-names>V</given-names></name><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Chi</surname><given-names>C-Y</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Roynard</surname><given-names>M</given-names></name><name><surname>Fleckenstein</surname><given-names>B</given-names></name><name><surname>Rozenberg</surname><given-names>F</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Ku</surname><given-names>C-L</given-names></name><name><surname>Seeleuthner</surname><given-names>Y</given-names></name><name><surname>Béziat</surname><given-names>V</given-names></name><name><surname>Marr</surname><given-names>N</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inherited human IFN-γ deficiency underlies mycobacterial disease</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>3158</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1172/JCI135460</pub-id><pub-id pub-id-type="pmid">32163377</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketelut-Carneiro</surname><given-names>N</given-names></name><name><surname>Souza</surname><given-names>COS</given-names></name><name><surname>Benevides</surname><given-names>L</given-names></name><name><surname>Gardinassi</surname><given-names>LG</given-names></name><name><surname>Silva</surname><given-names>MC</given-names></name><name><surname>Tavares</surname><given-names>LA</given-names></name><name><surname>Zamboni</surname><given-names>DS</given-names></name><name><surname>Silva</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Caspase-11-dependent IL-1α release boosts Th17 immunity against Paracoccidioides brasiliensis</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007990</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007990</pub-id><pub-id pub-id-type="pmid">31425553</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khader</surname><given-names>SA</given-names></name><name><surname>Bell</surname><given-names>GK</given-names></name><name><surname>Pearl</surname><given-names>JE</given-names></name><name><surname>Fountain</surname><given-names>JJ</given-names></name><name><surname>Rangel-Moreno</surname><given-names>J</given-names></name><name><surname>Cilley</surname><given-names>GE</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Eaton</surname><given-names>SM</given-names></name><name><surname>Gaffen</surname><given-names>SL</given-names></name><name><surname>Swain</surname><given-names>SL</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>Haynes</surname><given-names>L</given-names></name><name><surname>Randall</surname><given-names>TD</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during <italic>Mycobacterium tuberculosis</italic> challenge</article-title><source>Nature Immunology</source><volume>8</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/ni1449</pub-id><pub-id pub-id-type="pmid">17351619</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimmey</surname><given-names>JM</given-names></name><name><surname>Huynh</surname><given-names>JP</given-names></name><name><surname>Weiss</surname><given-names>LA</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kambal</surname><given-names>A</given-names></name><name><surname>Debnath</surname><given-names>J</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Stallings</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Unique role for ATG5 in neutrophil-mediated immunopathology during <italic>M. tuberculosis</italic> infection</article-title><source>Nature</source><volume>528</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nature16451</pub-id><pub-id pub-id-type="pmid">26649827</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolaczkowska</surname><given-names>E</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neutrophil recruitment and function in health and inflammation</article-title><source>Nature Reviews. Immunology</source><volume>13</volume><fpage>159</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nri3399</pub-id><pub-id pub-id-type="pmid">23435331</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Korotkevich</surname><given-names>G</given-names></name><name><surname>Sukhov</surname><given-names>V</given-names></name><name><surname>Budin</surname><given-names>N</given-names></name><name><surname>Shpak</surname><given-names>B</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fast gene set enrichment analysis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/060012</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>NP</given-names></name><name><surname>Moideen</surname><given-names>K</given-names></name><name><surname>Nancy</surname><given-names>A</given-names></name><name><surname>Viswanathan</surname><given-names>V</given-names></name><name><surname>Thiruvengadam</surname><given-names>K</given-names></name><name><surname>Sivakumar</surname><given-names>S</given-names></name><name><surname>Hissar</surname><given-names>S</given-names></name><name><surname>Nair</surname><given-names>D</given-names></name><name><surname>Banurekha</surname><given-names>VV</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes among patients with pulmonary tuberculosis</article-title><source>JAMA Network Open</source><volume>3</volume><elocation-id>e2027754</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.27754</pub-id><pub-id pub-id-type="pmid">33258908</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>NP</given-names></name><name><surname>Moideen</surname><given-names>K</given-names></name><name><surname>Nancy</surname><given-names>A</given-names></name><name><surname>Viswanathan</surname><given-names>V</given-names></name><name><surname>Thiruvengadam</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>D</given-names></name><name><surname>Banurekha</surname><given-names>VV</given-names></name><name><surname>Sivakumar</surname><given-names>S</given-names></name><name><surname>Hissar</surname><given-names>S</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Plasma chemokines are baseline predictors of unfavorable treatment outcomes in pulmonary tuberculosis</article-title><source>Clinical Infectious Diseases</source><volume>73</volume><fpage>e3419</fpage><lpage>e3427</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1104</pub-id><pub-id pub-id-type="pmid">32766812</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>D</given-names></name><name><surname>De Sousa</surname><given-names>D</given-names></name><name><surname>Quast</surname><given-names>K</given-names></name><name><surname>Fundel-Clemens</surname><given-names>K</given-names></name><name><surname>Erjefält</surname><given-names>JS</given-names></name><name><surname>Sandén</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>HJ</given-names></name><name><surname>Kästle</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>R</given-names></name><name><surname>Menden</surname><given-names>K</given-names></name><name><surname>Delic</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma</article-title><source>Respiratory Research</source><volume>22</volume><elocation-id>158</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-021-01743-7</pub-id><pub-id pub-id-type="pmid">34022896</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langrish</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Basham</surname><given-names>B</given-names></name><name><surname>Sedgwick</surname><given-names>JD</given-names></name><name><surname>McClanahan</surname><given-names>T</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id><pub-id pub-id-type="pmid">15657292</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Eynon</surname><given-names>EE</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Kang</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulating human Th17 cells via differential expression of IL-1 receptor</article-title><source>Blood</source><volume>115</volume><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-08-236521</pub-id><pub-id pub-id-type="pmid">19965648</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Boyce</surname><given-names>S</given-names></name><name><surname>Powers</surname><given-names>J</given-names></name><name><surname>Baer</surname><given-names>C</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Behar</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD11cHi monocyte-derived macrophages are a major cellular compartment infected by <italic>Mycobacterium tuberculosis</italic></article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008621</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008621</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leliefeld</surname><given-names>PHC</given-names></name><name><surname>Pillay</surname><given-names>J</given-names></name><name><surname>Vrisekoop</surname><given-names>N</given-names></name><name><surname>Heeres</surname><given-names>M</given-names></name><name><surname>Tak</surname><given-names>T</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Rooijakkers</surname><given-names>SHM</given-names></name><name><surname>Kuijpers</surname><given-names>TW</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential antibacterial control by neutrophil subsets</article-title><source>Blood Advances</source><volume>2</volume><fpage>1344</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017015578</pub-id><pub-id pub-id-type="pmid">29895625</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>HP</given-names></name><name><surname>Grespan</surname><given-names>R</given-names></name><name><surname>Vieira</surname><given-names>SM</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Verri</surname><given-names>WA</given-names><suffix>Jr</suffix></name><name><surname>Fernandes</surname><given-names>KSS</given-names></name><name><surname>Souto</surname><given-names>FO</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Ferreira</surname><given-names>SH</given-names></name><name><surname>Liew</surname><given-names>FY</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production</article-title><source>PNAS</source><volume>106</volume><fpage>5954</fpage><lpage>5959</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812782106</pub-id><pub-id pub-id-type="pmid">19289819</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Newport</surname><given-names>MJ</given-names></name><name><surname>Kalabalikis</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>N</given-names></name><name><surname>D’Souza</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>IN</given-names></name><name><surname>Lenicker</surname><given-names>HM</given-names></name><name><surname>Vassallo Agius</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>EG</given-names></name><name><surname>Thrasher</surname><given-names>A</given-names></name><name><surname>Blackwell</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?</article-title><source>The Lancet</source><volume>345</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)90059-4</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Soneson</surname><given-names>C</given-names></name><name><surname>Hickey</surname><given-names>PF</given-names></name><name><surname>Johnson</surname><given-names>LK</given-names></name><name><surname>Pierce</surname><given-names>NT</given-names></name><name><surname>Shepherd</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Patro</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tximeta: Reference sequence checksums for provenance identification in RNA-seq</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>e1007664</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007664</pub-id><pub-id pub-id-type="pmid">32097405</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovewell</surname><given-names>RR</given-names></name><name><surname>Baer</surname><given-names>CE</given-names></name><name><surname>Mishra</surname><given-names>BB</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Granulocytes act as a niche for <italic>Mycobacterium tuberculosis</italic> growth</article-title><source>Mucosal Immunology</source><volume>14</volume><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/s41385-020-0300-z</pub-id><pub-id pub-id-type="pmid">32483198</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>DM</given-names></name><name><surname>Bandara</surname><given-names>AK</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Barker</surname><given-names>RD</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Griffiths</surname><given-names>CJ</given-names></name><name><surname>Martineau</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neutrophilia independently predicts death in tuberculosis</article-title><source>The European Respiratory Journal</source><volume>42</volume><fpage>1752</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1183/09031936.00140913</pub-id><pub-id pub-id-type="pmid">24114967</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>DM</given-names></name><name><surname>Demaret</surname><given-names>J</given-names></name><name><surname>Bangani</surname><given-names>N</given-names></name><name><surname>Nakiwala</surname><given-names>JK</given-names></name><name><surname>Goliath</surname><given-names>R</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Martineau</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential effect of viable versus necrotic neutrophils on <italic>Mycobacterium tuberculosis</italic> growth and cytokine induction in whole blood</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>903</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00903</pub-id><pub-id pub-id-type="pmid">29755473</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahdaviani</surname><given-names>SA</given-names></name><name><surname>Fallahi</surname><given-names>M</given-names></name><name><surname>Jamee</surname><given-names>M</given-names></name><name><surname>Marjani</surname><given-names>M</given-names></name><name><surname>Tabarsi</surname><given-names>P</given-names></name><name><surname>Moniri</surname><given-names>A</given-names></name><name><surname>Farnia</surname><given-names>P</given-names></name><name><surname>Daneshmandi</surname><given-names>Z</given-names></name><name><surname>Parvaneh</surname><given-names>N</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Mansouri</surname><given-names>D</given-names></name><name><surname>Velayati</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series</article-title><source>Annals of Clinical Microbiology and Antimicrobials</source><volume>21</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/s12941-022-00500-y</pub-id><pub-id pub-id-type="pmid">35232430</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maloney</surname><given-names>CG</given-names></name><name><surname>Kutchera</surname><given-names>WA</given-names></name><name><surname>Albertine</surname><given-names>KH</given-names></name><name><surname>McIntyre</surname><given-names>TM</given-names></name><name><surname>Prescott</surname><given-names>SM</given-names></name><name><surname>Zimmerman</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils</article-title><source>Journal of Immunology</source><volume>160</volume><fpage>1402</fpage><lpage>1410</lpage><pub-id pub-id-type="pmid">9570560</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martineau</surname><given-names>AR</given-names></name><name><surname>Newton</surname><given-names>SM</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Kampmann</surname><given-names>B</given-names></name><name><surname>Hall</surname><given-names>BM</given-names></name><name><surname>Nawroly</surname><given-names>N</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><name><surname>Griffiths</surname><given-names>CJ</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neutrophil-mediated innate immune resistance to mycobacteria</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>1988</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1172/JCI31097</pub-id><pub-id pub-id-type="pmid">17607367</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Granulocytes subsets and their divergent functions in host resistance to <italic>Mycobacterium tuberculosis</italic> - a “tipping-point” model of disease exacerbation</article-title><source>Current Opinion in Immunology</source><volume>84</volume><elocation-id>102365</elocation-id><pub-id pub-id-type="doi">10.1016/j.coi.2023.102365</pub-id><pub-id pub-id-type="pmid">37437471</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>KHG</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>IL-17 and IL-17-producing cells in protection versus pathology</article-title><source>Nature Reviews. Immunology</source><volume>23</volume><fpage>38</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00746-9</pub-id><pub-id pub-id-type="pmid">35790881</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>BB</given-names></name><name><surname>Lovewell</surname><given-names>RR</given-names></name><name><surname>Olive</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Eugenin</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Phuah</surname><given-names>JY</given-names></name><name><surname>Long</surname><given-names>JE</given-names></name><name><surname>Dubuke</surname><given-names>ML</given-names></name><name><surname>Palace</surname><given-names>SG</given-names></name><name><surname>Goguen</surname><given-names>JD</given-names></name><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Nambi</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Booty</surname><given-names>MG</given-names></name><name><surname>Baer</surname><given-names>CE</given-names></name><name><surname>Shaffer</surname><given-names>SA</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>McCormick</surname><given-names>BA</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis</article-title><source>Nature Microbiology</source><volume>2</volume><elocation-id>17072</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.72</pub-id><pub-id pub-id-type="pmid">28504669</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyahara</surname><given-names>R</given-names></name><name><surname>Piyaworawong</surname><given-names>S</given-names></name><name><surname>Naranbhai</surname><given-names>V</given-names></name><name><surname>Prachamat</surname><given-names>P</given-names></name><name><surname>Kriengwatanapong</surname><given-names>P</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Wongyai</surname><given-names>J</given-names></name><name><surname>Bupachat</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>N</given-names></name><name><surname>Summanapan</surname><given-names>S</given-names></name><name><surname>Mahasirimongkol</surname><given-names>S</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predicting the risk of pulmonary tuberculosis based on the neutrophil-to-lymphocyte ratio at TB screening in HIV-infected individuals</article-title><source>BMC Infectious Diseases</source><volume>19</volume><elocation-id>667</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-4292-9</pub-id><pub-id pub-id-type="pmid">31357936</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Rodriguez-Rosales</surname><given-names>YA</given-names></name><name><surname>Gillard</surname><given-names>J</given-names></name><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Theunissen</surname><given-names>K</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>de Bont</surname><given-names>CM</given-names></name><name><surname>Negishi</surname><given-names>Y</given-names></name><name><surname>Fok</surname><given-names>ET</given-names></name><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Koeken</surname><given-names>V</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Pruijn</surname><given-names>GJM</given-names></name><name><surname>Fenwick</surname><given-names>C</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Joosten</surname><given-names>I</given-names></name><name><surname>Koenen</surname><given-names>H</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Diavatopoulos</surname><given-names>DA</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BCG vaccination induces long-term functional reprogramming of human neutrophils</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108387</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108387</pub-id><pub-id pub-id-type="pmid">33207187</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Obenchain</surname><given-names>V</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Pagès</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>SummarizedExperiment: summarizedexperiment container</data-title><version designator="version 1.22.0">version 1.22.0</version><source>R Package</source></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Muramatsu</surname><given-names>H</given-names></name><name><surname>Arakawa</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immunonutritional status and pulmonary cavitation in patients with tuberculosis: A revisit with an assessment of neutrophil/lymphocyte ratio</article-title><source>Respiratory Investigation</source><volume>57</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.resinv.2018.08.007</pub-id><pub-id pub-id-type="pmid">30528689</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>B</given-names></name><name><surname>Behar</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>2251</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1084/jem.20110919</pub-id><pub-id pub-id-type="pmid">21967766</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitani</surname><given-names>G</given-names></name><name><surname>Acosta-Rodriguez</surname><given-names>EV</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells</article-title><source>European Journal of Immunology</source><volume>39</volume><fpage>1301</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1002/eji.200838969</pub-id><pub-id pub-id-type="pmid">19384872</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nwongbouwoh Muefong</surname><given-names>C</given-names></name><name><surname>Owolabi</surname><given-names>O</given-names></name><name><surname>Donkor</surname><given-names>S</given-names></name><name><surname>Charalambous</surname><given-names>S</given-names></name><name><surname>Bakuli</surname><given-names>A</given-names></name><name><surname>Rachow</surname><given-names>A</given-names></name><name><surname>Geldmacher</surname><given-names>C</given-names></name><name><surname>Sutherland</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neutrophils contribute to severity of tuberculosis pathology and recovery from lung damage pre- and posttreatment</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>1757</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab729</pub-id><pub-id pub-id-type="pmid">34427644</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>M</given-names></name><name><surname>Behr</surname><given-names>MA</given-names></name><name><surname>Dowdy</surname><given-names>D</given-names></name><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Boehme</surname><given-names>CC</given-names></name><name><surname>Ginsberg</surname><given-names>A</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Spigelman</surname><given-names>M</given-names></name><name><surname>Getahun</surname><given-names>H</given-names></name><name><surname>Menzies</surname><given-names>D</given-names></name><name><surname>Raviglione</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tuberculosis</article-title><source>Nature Reviews. Disease Primers</source><volume>2</volume><elocation-id>16076</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2016.76</pub-id><pub-id pub-id-type="pmid">27784885</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulissen</surname><given-names>SMJ</given-names></name><name><surname>van Hamburg</surname><given-names>JP</given-names></name><name><surname>Davelaar</surname><given-names>N</given-names></name><name><surname>Asmawidjaja</surname><given-names>PS</given-names></name><name><surname>Hazes</surname><given-names>JMW</given-names></name><name><surname>Lubberts</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23</article-title><source>Journal of Immunology</source><volume>191</volume><fpage>1364</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300274</pub-id><pub-id pub-id-type="pmid">23817417</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavan Kumar</surname><given-names>N</given-names></name><name><surname>Moideen</surname><given-names>K</given-names></name><name><surname>Nancy</surname><given-names>A</given-names></name><name><surname>Viswanathan</surname><given-names>V</given-names></name><name><surname>Shruthi</surname><given-names>BS</given-names></name><name><surname>Shanmugam</surname><given-names>S</given-names></name><name><surname>Hissar</surname><given-names>S</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Plasma eicosanoid levels in tuberculosis and tuberculosis-diabetes co-morbidity are associated with lung pathology and bacterial burden</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>9</volume><elocation-id>335</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2019.00335</pub-id><pub-id pub-id-type="pmid">31632923</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearl</surname><given-names>JE</given-names></name><name><surname>Saunders</surname><given-names>B</given-names></name><name><surname>Ehlers</surname><given-names>S</given-names></name><name><surname>Orme</surname><given-names>IM</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse</article-title><source>Cellular Immunology</source><volume>211</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1006/cimm.2001.1819</pub-id><pub-id pub-id-type="pmid">11585387</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peres</surname><given-names>CM</given-names></name><name><surname>de Paula</surname><given-names>L</given-names></name><name><surname>Medeiros</surname><given-names>AI</given-names></name><name><surname>Sorgi</surname><given-names>CA</given-names></name><name><surname>Soares</surname><given-names>EG</given-names></name><name><surname>Carlos</surname><given-names>D</given-names></name><name><surname>Peters-Golden</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>CL</given-names></name><name><surname>Faccioli</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inhibition of leukotriene biosynthesis abrogates the host control of <italic>Mycobacterium tuberculosis</italic></article-title><source>Microbes and Infection</source><volume>9</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2007.01.006</pub-id><pub-id pub-id-type="pmid">17347013</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Revisiting the role of the granuloma in tuberculosis</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>352</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/nri3211</pub-id><pub-id pub-id-type="pmid">22517424</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2021">2021</year><data-title>R: a language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>N</given-names></name><name><surname>du Bruyn</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Assessment of treatment response in tuberculosis</article-title><source>Expert Review of Respiratory Medicine</source><volume>10</volume><fpage>643</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1586/17476348.2016.1166960</pub-id><pub-id pub-id-type="pmid">27030924</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadikot</surname><given-names>RT</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Azim</surname><given-names>AC</given-names></name><name><surname>Joo</surname><given-names>M</given-names></name><name><surname>Dey</surname><given-names>SK</given-names></name><name><surname>Breyer</surname><given-names>RM</given-names></name><name><surname>Peebles</surname><given-names>RS</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name><name><surname>Christman</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Bacterial clearance of <italic>Pseudomonas aeruginosa</italic> is enhanced by the inhibition of COX-2</article-title><source>European Journal of Immunology</source><volume>37</volume><fpage>1001</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1002/eji.200636636</pub-id><pub-id pub-id-type="pmid">17330822</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scapini</surname><given-names>P</given-names></name><name><surname>Marini</surname><given-names>O</given-names></name><name><surname>Tecchio</surname><given-names>C</given-names></name><name><surname>Cassatella</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Human neutrophils in the saga of cellular heterogeneity: insights and open questions</article-title><source>Immunological Reviews</source><volume>273</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/imr.12448</pub-id><pub-id pub-id-type="pmid">27558327</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serezani</surname><given-names>CH</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Ballinger</surname><given-names>MN</given-names></name><name><surname>Moore</surname><given-names>BB</given-names></name><name><surname>Aronoff</surname><given-names>DM</given-names></name><name><surname>Peters-Golden</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>37</volume><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2007-0153OC</pub-id><pub-id pub-id-type="pmid">17585108</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppe</surname><given-names>AEF</given-names></name><name><surname>Edelmann</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Roles of eicosanoids in regulating inflammation and neutrophil migration as an innate host response to bacterial infections</article-title><source>Infection and Immunity</source><volume>89</volume><elocation-id>e0009521</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00095-21</pub-id><pub-id pub-id-type="pmid">34031130</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>MT</given-names></name><name><surname>Silva</surname><given-names>MN</given-names></name><name><surname>Appelberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Neutrophil-macrophage cooperation in the host defence against mycobacterial infections</article-title><source>Microbial Pathogenesis</source><volume>6</volume><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(89)90079-x</pub-id><pub-id pub-id-type="pmid">2770507</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>AP</given-names></name><name><surname>Kwong Chung</surname><given-names>CKC</given-names></name><name><surname>Choice</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>EJ</given-names></name><name><surname>Jacobs</surname><given-names>G</given-names></name><name><surname>van Rensburg</surname><given-names>EJ</given-names></name><name><surname>Khomba</surname><given-names>G</given-names></name><name><surname>de Kock</surname><given-names>M</given-names></name><name><surname>Lerumo</surname><given-names>L</given-names></name><name><surname>Makhethe</surname><given-names>L</given-names></name><name><surname>Maneli</surname><given-names>MH</given-names></name><name><surname>Pienaar</surname><given-names>B</given-names></name><name><surname>Smit</surname><given-names>E</given-names></name><name><surname>Tena-Coki</surname><given-names>NG</given-names></name><name><surname>van Wyk</surname><given-names>L</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Scriba</surname><given-names>TJ</given-names></name><name><surname>Hanekom</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns</article-title><source>The Journal of Infectious Diseases</source><volume>207</volume><fpage>1084</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis941</pub-id><pub-id pub-id-type="pmid">23293360</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryana</surname><given-names>K</given-names></name><name><surname>Dharmesti</surname><given-names>NWW</given-names></name><name><surname>Rai</surname><given-names>IBN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>High pretreatment level of neutrophil to lymphocyte ratio, monocyte to lymphocyte ratio and other factors associated with delayed sputum conversion in patients with pulmonary tuberculosis</article-title><source>Infection and Drug Resistance</source><volume>15</volume><fpage>5455</fpage><lpage>5462</lpage><pub-id pub-id-type="doi">10.2147/IDR.S380166</pub-id><pub-id pub-id-type="pmid">36131811</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>SG</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Ryffel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RORγt+IL-17+ neutrophils play a critical role in hepatic ischemia-reperfusion injury</article-title><source>Journal of Molecular Cell Biology</source><volume>5</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjs065</pub-id><pub-id pub-id-type="pmid">23362310</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Leal</surname><given-names>SM</given-names><suffix>Jr</suffix></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Howell</surname><given-names>SJ</given-names></name><name><surname>Cobb</surname><given-names>BA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Pearlman</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2</article-title><source>Nature Immunology</source><volume>15</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/ni.2797</pub-id><pub-id pub-id-type="pmid">24362892</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>MWL</given-names></name><name><surname>Bowman</surname><given-names>EP</given-names></name><name><surname>McElwee</surname><given-names>JJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases</article-title><source>Nature Medicine</source><volume>21</volume><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/nm.3895</pub-id><pub-id pub-id-type="pmid">26121196</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>EG</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Malherbe</surname><given-names>ST</given-names></name><name><surname>Shankar</surname><given-names>S</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Valvo</surname><given-names>J</given-names></name><name><surname>Ronacher</surname><given-names>K</given-names></name><name><surname>Tromp</surname><given-names>G</given-names></name><name><surname>Tabb</surname><given-names>DL</given-names></name><name><surname>Alland</surname><given-names>D</given-names></name><name><surname>Shenai</surname><given-names>S</given-names></name><name><surname>Via</surname><given-names>LE</given-names></name><name><surname>Warwick</surname><given-names>J</given-names></name><name><surname>Aderem</surname><given-names>A</given-names></name><name><surname>Scriba</surname><given-names>TJ</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Walzl</surname><given-names>G</given-names></name><name><surname>Zak</surname><given-names>DE</given-names></name><name><surname>Du Plessis</surname><given-names>N</given-names></name><name><surname>Loxton</surname><given-names>AG</given-names></name><name><surname>Chegou</surname><given-names>NN</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Host blood RNA signatures predict the outcome of tuberculosis treatment</article-title><source>Tuberculosis</source><volume>107</volume><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2017.08.004</pub-id><pub-id pub-id-type="pmid">29050771</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>DM</given-names></name><name><surname>Vary</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>Walsh</surname><given-names>GS</given-names></name><name><surname>Dunstan</surname><given-names>SJ</given-names></name><name><surname>Bang</surname><given-names>ND</given-names></name><name><surname>Hagge</surname><given-names>DA</given-names></name><name><surname>Khadge</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>M-C</given-names></name><name><surname>Hawn</surname><given-names>TR</given-names></name><name><surname>Moens</surname><given-names>CB</given-names></name><name><surname>Ramakrishnan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans</article-title><source>Cell</source><volume>140</volume><fpage>717</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.013</pub-id><pub-id pub-id-type="pmid">20211140</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrado</surname><given-names>E</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-17 and Th17 cells in tuberculosis</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>21</volume><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2010.10.004</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Hanafusa</surname><given-names>T</given-names></name><name><surname>Herndon</surname><given-names>DN</given-names></name><name><surname>Suzuki</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Immunity</source><volume>21</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.07.006</pub-id><pub-id pub-id-type="pmid">15308102</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Ibrahim</surname><given-names>JG</given-names></name><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nonparametric expression analysis using inferential replicate counts</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e105</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz622</pub-id><pub-id pub-id-type="pmid">31372651</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100966.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> study examines the role of IL17-producing Ly6G PMNs as a reservoir for <italic>Mycobacterium tuberculosis</italic> to evade host killing activated by BCG immunisation. The authors provide <bold>solid</bold> data reporting that IL17-producing polymorphonuclear neutrophils harbour a significant bacterial load in both wild-type and IFNg-/- mice and that targeting IL17 and Cox2 improved disease outcomes whilst enhancing BCG efficacy. The specific contribution of neutrophil-derived IL-17 to disease pathogenesis remains to be definitively established through direct demonstration of IL-17 production by neutrophils and targeted depletion studies.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100966.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study, Sharma et al. demonstrated that Ly6G+ granulocytes (Gra cells) serve as the primary reservoirs for intracellular Mtb in infected wild-type mice and that excessive infiltration of these cells is associated with severe bacteremia in genetically susceptible IFNγ-/- mice. Notably, neutralizing IL-17 or inhibiting COX2 reversed the excessive infiltration of Ly6G+Gra cells, mitigated the associated pathology, and improved survival in these susceptible mice. Additionally, Ly6G+Gra cells were identified as a major source of IL-17 in both wild-type and IFNγ-/- mice. Inhibition of RORγt or COX2 further reduced the intracellular bacterial burden in Ly6G+Gra cells and improved lung pathology.</p><p>Of particular interest, COX2 inhibition in wild-type mice also enhanced the efficacy of the BCG vaccine by targeting the Ly6G+Gra-resident Mtb population.</p><p>Strengths:</p><p>The experimental results showing improved BCG-mediated protective immunity through targeting IL-17-producing Ly6G+ cells and COX2 are compelling and will likely generate significant interest in the field. Overall, this study presents important findings, suggesting that the IL-17-COX2 axis could be a critical target for designing innovative vaccination strategies for TB.</p><p>Comments on revisions:</p><p>This article is of significant interest for the research field. In the revised version of the manuscript the authors have addressed the concerns raised during initial review. I do not have further concerns.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100966.3.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors examine how distinct cellular environments differentially control Mtb following BCG vaccination. The key findings are that IL17 producing PMNs harbor a significant Mtb load in both wild type and IFNg-/- mice. Targeting IL17, Cox2, and Rorgt, improved disease in combination but not alone and enhances BCG efficacy over 12 weeks and neutrophils/IL17 are associated with treatment failure in humans. The authors suggest that targeting these pathways, especially in MSMD patients may improve disease outcomes.</p><p>Strengths:</p><p>The experimental approach is generally sound and consists of low dose aerosol infections with distinct readouts including cell sorting followed by CFU, histopathology and RNA sequencing analysis. By combining genetic approaches and chemical/antibody treatments, the authors can probe these pathways effectively.</p><p>Understanding how distinct inflammatory pathways contribute to control or worsen Mtb disease is important and thus, the results will be of great interest to the Mtb field.</p><p>Uncovering a neutrophil population that is refractory to BCG-mediated control can help to better define key markers for vaccine efficacy</p><p>Weaknesses:</p><p>Several of the key findings in mice have previously been shown (albeit with less sophisticated experimentation) and human disease and neutrophils are well described - thus the real new finding is how intracellular Mtb in neutrophils are more refractory to BCG-mediated control and modulating IL17 and inflammation can alter this.</p><p>There is a lack of direct evidence that the neutrophils are producing IL-17 or showing that specifically removing IL17 neutrophils has an effect on disease. Thus, many of these data are correlative, or have modest phenotypes. For example if blocking IL17 or alone does not impact disease alone the conclusion that these IL17+ neutrophils limits protection as noted in the title is is not fully supported. The inhibitors used are not cell-type specific.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100966.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Priya</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Raman Deep</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Binayak</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Panwar</surname><given-names>Varnika</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Mrinmoy</given-names></name><role specific-use="author">Author</role><aff><institution>University College Cork</institution><addr-line><named-content content-type="city">Cork</named-content></addr-line><country>Ireland</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Lakshya Veer</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Neharika</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Chaturvedi</surname><given-names>Shivam</given-names></name><role specific-use="author">Author</role><aff><institution>ICGEB</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Mehra</surname><given-names>Lalita</given-names></name><role specific-use="author">Author</role><aff><institution>All India Institute of Medical Sciences</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Rathee</surname><given-names>Aditya</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shilpa</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Foo</surname><given-names>Shihui</given-names></name><role specific-use="author">Author</role><aff><institution>Agency for Science, Technology and Research</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Andrea</given-names></name><role specific-use="author">Author</role><aff><institution>Agency for Science, Technology and Research</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib><contrib contrib-type="author"><name><surname>N</surname><given-names>Pavan Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>ICMR-National Institute for Research in Tuberculosis</institution><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Prasenjit</given-names></name><role specific-use="author">Author</role><aff><institution>All India Institute of Medical Sciences</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Viswanathan</surname><given-names>Vijay</given-names></name><role specific-use="author">Author</role><aff><institution>Prof M Viswanathan Diabetes Research Center</institution><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Kornfeld</surname><given-names>Hardy</given-names></name><role specific-use="author">Author</role><aff><institution>University of Massachusetts Chan Medical School</institution><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Howland</surname><given-names>Shanshan W</given-names></name><role specific-use="author">Author</role><aff><institution>Agency for Science, Technology and Research (A*STAR)</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib><contrib contrib-type="author"><name><surname>Babu</surname><given-names>Subash</given-names></name><role specific-use="author">Author</role><aff><institution>NIH-International Center of Excellence in Research</institution><addr-line><named-content content-type="city">Chennai</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Nandicoori</surname><given-names>Vinay Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Immunology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Singhal</surname><given-names>Amit</given-names></name><role specific-use="author">Author</role><aff><institution>Infectious Diseases Labs (ID labs), Agency for Science, Technology and Research (A*STAR)</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Dhiraj</given-names></name><role specific-use="author">Author</role><aff><institution>International Centre for Genetic Engineering and Biotechnology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>Recruitment of neutrophils to the lungs is known to drive susceptibility to infection with <italic>M. tuberculosis</italic>. In this study, the authors present data in support of the hypothesis that neutrophil production of the cytokine IL-17 underlies the detrimental effect of neutrophils on disease. They claim that neutrophils harbor a large fraction of Mtb during infection, and are a major source of IL-17. To explore the effects of blocking IL-17 signaling during primary infection, they use IL-17 blocking antibodies, SR221 (an inverse agonist of Th17 differentiation), and celecoxib, which they claim blocks Th17 differentiation, and observe modest improvements in bacterial burdens in both WT and IFN-γ deficient mice using the combination of IL-17 blockade with celecoxib during primary infection. Celecoxib enhances control of infection after BCG vaccination.</p></disp-quote><p>Thank you for the summary.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The most novel finding in the paper is that treatment with celecoxib significantly enhances control of infection in BCG-vaccinated mice that have been challenged with Mtb. It was already known that NSAID treatments can improve primary infection with Mtb.</p></disp-quote><p>Thank you.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The major claim of the manuscript - that neutrophils produce IL-17 that is detrimental to the host - is not strongly supported by the data. Data demonstrating neutrophil production of IL17 lacks rigor.</p></disp-quote><p>Our response: Neutrophil production of IL-17 is supported by two independent methods/ techniques in the current version:</p><p>(1) Through Flow cytometry- a large fraction of Ly6G<sup>+</sup>CD11b<sup>+</sup> cells from the lungs of Mtb-infected mice were also positive for IL-17 (Fig. 3C).</p><p>(2) IFA co-staining of Ly6G <sup>+</sup> cells with IL-17 in the lung sections from Mtb-infected mice (Fig. 3 E_G and Fig. 4H, Fig. 5I). For most of these IFA data, we provide quantified plots to show IL17<sup>+</sup>Ly6G<sup>+</sup> cells.</p><p>(3) Most importantly, conditions that inhibited IL-17 levels and controlled infection also showed a decline in IL-17 staining in Ly6G<sup>+</sup> cells.</p><p>Our efforts on IL-17 ELISPOT assay were not very successful and it needs further standardization.</p><p>Several independent publications support the production of IL-17 by neutrophils (Li et al. 2010; Katayama et al. 2013; Lin et al. 2011). For example, neutrophils have been identified as a source of IL-17 in human psoriatic lesions (Lin et al. 2011), in neuroinflammation induced by traumatic brain injury (Xu et al. 2023) and in several mouse models of infectious and autoimmune inflammation (Ferretti et al. 2003; Hoshino et al. 2008) (Li et al. 2010).</p><disp-quote content-type="editor-comment"><p>The experiments examining the effects of inhibitors of IL-17 on the outcome of infection are very difficult to interpret. First, treatment with IL-17 inhibitors alone has no impact on bacterial burdens in the lung, either in WT or IFN-γ KO mice. This suggests that IL-17 does not play a detrimental role during infection. Modest effects are observed using the combination of IL-17 blocking drugs and celecoxib, however, the interpretation of these results mechanistically is complicated. Celecoxib is not a specific inhibitor of Th17. Indeed, it affects levels of PGE2, which is known to have numerous impacts on Mtb infection separate from any effect on IL-17 production, as well as other eicosanoids.</p></disp-quote><p>The reviewer correctly says that Celecoxib is not a specific inhibitor of Th17. However, COX2 inhibition does have an effect on IL-17 levels, and numerous reports support this observation (Paulissen et al. 2013; Napolitani et al. 2009; Lemos et al. 2009).</p><p>(1) The detrimental role of IL-17 is obvious in the IFNγ KO experiment, where IL-17 neutralization led to a significant improvement in the lung pathology.</p><p>(2) In the highly susceptible IFNγ KO mice, IL-17 neutralization alone extended the survival of mice by ~10 days.</p><p>(3) IL-17 production independent of IL-23 is known to require PGE2 (Paulissen et al. 2013; Polese et al. 2021). In either WT or IFNγ KO mice, in contrast to IL-17 levels, we observed a decline in IL-23 levels. The PGE2 dependence of IL-17 production is obvious in the WT mice, where celecoxib abrogated IL-17 production.</p><p>(4) While deciding the impact of celecoxib or IL17 inhibition, looking at the cumulative readout of lung CFU, spleen CFU, Ly6G<sup>+</sup> cell recruitment, Ly6G<sup>+</sup> cell-resident Mtb pool and overall pathology, the effects are quite significant.</p><p>(5) Finally, in the revised manuscript, we provide additional results on the effect of SR2211 in BCG-vaccinated animals. It shows the direct impact of IL-17 inhibition on the BCG vaccine efficacy in WT mice.</p><disp-quote content-type="editor-comment"><p>Finally, the human data simply demonstrates that neutrophils and IL-17 both are higher in patients who experience relapse after treatment for TB, which is expected and does not support their specific hypothesis.</p></disp-quote><p>We disagree with the above statement. It also contradicts reviewers’ own assessments in one of the comments below, where a protective role of IL-17 is referred to. The literature lacks consensus in terms of a protective or pathological role of IL-17 in TB. Therefore, it was not expected to see higher IL-17 in patients who experienced relapse, death, or failed treatment outcomes. We do not have evidence from human subjects whether neutrophil-derived IL-17 has a similar pathological role as observed in mice. However, higher IL-17 in failed outcome cases confirm the central theme that IL-17 is pathological in both human and mouse models.</p><disp-quote content-type="editor-comment"><p>The use of genetic ablation of IL-17 production specifically in neutrophils and/or IL-17R in mice would greatly enhance the rigor of this study.</p></disp-quote><p>The reviewer’s point is well-taken. Having a genetic ablation of IL-17 production, specifically in the neutrophils, would be excellent. At present, however, we lack this resource. For the revised manuscript, we include the data with SR2211, a direct inhibitor of RORgt and, therefore, IL-17, in BCG-vaccinated mice.</p><disp-quote content-type="editor-comment"><p>The authors do not address the fact that numerous studies have shown that IL-17 has a protective effect in the mouse model of TB in the context of vaccination.</p></disp-quote><p>Yes, there are a few articles that talk about the protective effect of IL-17 in the mouse model of TB in the context of vaccination (Khader et al. 2007; Desel et al. 2011; Choi et al. 2020). This part was discussed in the original manuscript (in the Introduction section). For the revised manuscript, we also provide results from the experiment where we blocked IL-17 production by inhibiting RORgt using SR2211 in BCG-vaccinated mice. The results clearly show IL-17 as a negative regulator of BCG-mediated protective immunity. We believe some of the reasons for the observed differences could be (1) in our study, we analysed IL-17 levels in the lung homogenates at late phases of infection, and (2) most published studies rely on ex vivo stimulation of immune cells to measure cytokine production, whereas we actually measured the cytokine levels in the lung homogenates. We will elaborate on these points in the revised version.</p><disp-quote content-type="editor-comment"><p>Finally, whether and how many times each animal experiment was repeated is unclear.</p></disp-quote><p>We provide the details of the number of experiments in the revised version. Briefly, the BCG vaccination experiment (Figure 1) and BCG vaccination with Celecoxib treatment experiment (Figure 6) were performed twice and thrice, respectively. The IL-17 neutralization experiment (Figure 4) and the SR2211 treatment experiment (Figure 5) were done once. We will add another SR2211 experiment data in the revised version.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this study, Sharma et al. demonstrated that Ly6G+ granulocytes (Gra cells) serve as the primary reservoirs for intracellular Mtb in infected wild-type mice and that excessive infiltration of these cells is associated with severe bacteremia in genetically susceptible IFNγ/- mice. Notably, neutralizing IL-17 or inhibiting COX2 reversed the excessive infiltration of Ly6G+Gra cells, mitigated the associated pathology, and improved survival in these susceptible mice. Additionally, Ly6G+Gra cells were identified as a major source of IL-17 in both wild-type and IFNγ-/- mice. Inhibition of RORγt or COX2 further reduced the intracellular bacterial burden in Ly6G+Gra cells and improved lung pathology.</p><p>Of particular interest, COX2 inhibition in wild-type mice also enhanced the efficacy of the BCG vaccine by targeting the Ly6G+Gra-resident Mtb population.</p></disp-quote><p>Thank you for the summary.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The experimental results showing improved BCG-mediated protective immunity through targeting IL-17-producing Ly6G+ cells and COX2 are compelling and will likely generate significant interest in the field. Overall, this study presents important findings, suggesting that the IL-17-COX2 axis could be a critical target for designing innovative vaccination strategies for TB.</p></disp-quote><p>Thank you for highlighting the overall strengths of the study.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>However, I have the following concerns regarding some of the conclusions drawn from the experiments, which require additional experimental evidence to support and strengthen the overall study.</p><p>Major Concerns:</p><p>(1) Ly6G+ Granulocytes as a Source of IL-17: The authors assert that Ly6G+ granulocytes are the major source of IL17 in wild-type and IFN-γ KO mice based on colocalization studies of Ly6G and IL-17. In Figure 3D, they report approximately 500 Ly6G+ cells expressing IL-17 in the Mtb-infected WT lung. Are these low numbers sufficient to drive inflammatory pathology? Additionally, have the authors evaluated these numbers in IFN-γ KO mice?</p></disp-quote><p>Thank you for pointing out the numbers in Fig. 3D It was our oversight to label the axis as No. of. For the observation that Ly6G<sup>+</sup> Gra are the major source of IL-17 in TB, we have used two separate strategies- (a) IFA and (b) FACS IL17<sup>+</sup> Ly6G<sup>+</sup> Gra/lung. For this data, only a part of the lung was used. For the revised manuscript, we provide the number of these cells at the whole lung level from Mtb-infected WT mice. Unfortunately, we did not evaluate these numbers in IFN-γ KO mice through FACS..</p><p>Our efforts to perform the IL-17 ELISpot assay on the sorted Ly6G<sup>+</sup>Gra from the lungs of Mtbinfected WT mice were unsuccessful. However, we provide a quantified representation of IFA of the tissue sections to stress upon the role of Ly6G<sup>+</sup> cells in IL-17 production in TB pathogenesis.</p><disp-quote content-type="editor-comment"><p>(2) Role of IL-17-Producing Ly6G Granulocytes in Pathology: The authors suggest that IL-17producing Ly6G granulocytes drive pathology in WT and IFN-γ KO mice. However, the data presented only demonstrate an association between IL-17<sup>+</sup> Ly6G cells and disease pathology. To strengthen their conclusion, the authors should deplete neutrophils in these mice to show that IL-17 expression, and consequently the pathology, is reduced.</p></disp-quote><p>Thank you for this suggestion. Neutrophil depletion studies in TB remain inconclusive. In some studies, neutrophil depletion helps the pathogen (Rankin et al. 2022; Pedrosa et al. 2000; Appelberg et al. 1995), and in others, it helps the host (Lovewell et al. 2021; Mishra et al. 2017). One reason for this variability is the stage of infection when neutrophil depletion was done. However, another crucial factor is the heterogeneity in the neutrophil population. There are reports that suggest neutrophil subtypes with protective versus pathological trajectories (Nwongbouwoh Muefong et al. 2022; Lyadova 2017; Hellebrekers, Vrisekoop, and Koenderman 2018; Leliefeld et al. 2018). Depleting the entire population using anti-Ly6G could impact this heterogeneity and may impact the inferences drawn.</p><p>A better approach would be to characterise this heterogeneous population, efforts towards which could be part of a separate study. Another direct approach could be Ly6G<sup>+</sup>-specific deletion of IL-17 function as part of a separate study.</p><p>For the revised manuscript, we provide results from the SR2211 experiment in BCG-vaccinated mice and other results to show the role of IL-17-producing Ly6G<sup>+</sup> Gra in TB pathology.</p><disp-quote content-type="editor-comment"><p>(3) IL-17 Secretion by Mtb-Infected Neutrophils: Do Mtb-infected neutrophils secrete IL-17 into the supernatants? This would serve as confirmation of neutrophil-derived IL-17. Additionally, are Ly6G<sup>+</sup> cells producing IL-17 and serving as pathogenic agents exclusively in vivo? The authors should provide comments on this.</p></disp-quote><p>Secretion of IL-17 by Mtb-infected neutrophils in vitro has been reported earlier (Hu et al. 2017). Our efforts to do a neutrophil IL-17 ELISPOT assay were not successful, and we are still standardising it. Whether there are a few neutrophil roles exclusively seen under in vivo conditions is an interesting proposition.</p><disp-quote content-type="editor-comment"><p>(4) Characterization of IL-17-Producing Ly6G+ Granulocytes: Are the IL-17-producing Ly6G+ granulocytes a mixed population of neutrophils and eosinophils, or are they exclusively neutrophils? Sorting these cells followed by Giemsa or eosin staining could clarify this.</p></disp-quote><p>This is a very important point. While usually eosinophils do not express Ly6G markers in laboratory mice, under specific contexts, including infections, eosinophils can express Ly6G. Since we have not characterized these potential Ly6G<sup>+</sup> sub-populations, that is one of the reasons we refer to the cell types as Ly6G<sup>+</sup> granulocytes, which do not exclude Ly6G<sup>+</sup> eosinophils. A detailed characterization of these subsets could be taken up as a separate study.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>The authors examine how distinct cellular environments differentially control Mtb following BCG vaccination. The key findings are that IL17-producing PMNs harbor a significant Mtb load in both wild-type and IFNg<sup>-/-</sup> mice. Targeting IL17 and Cox2 improved disease and enhanced BCG efficacy over 12 weeks and neutrophils/IL17 are associated with treatment failure in humans. The authors suggest that targeting these pathways, especially in MSMD patients may improve disease outcomes.</p></disp-quote><p>Thank you.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The experimental approach is generally sound and consists of low-dose aerosol infections with distinct readouts including cell sorting followed by CFU, histopathology, and RNA sequencing analysis. By combining genetic approaches and chemical/antibody treatments, the authors can probe these pathways effectively.</p><p>Understanding how distinct inflammatory pathways contribute to control or worsen Mtb disease is important and thus, the results will be of great interest to the Mtb field</p></disp-quote><p>Thank you.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>A major limitation of the current study is overlooking the role of non-hematopoietic cells in the IFNg/IL17/neutrophil response. Chimera studies from Ernst and colleagues (Desvignes and Ernst 2009) previously described this IDO-dependent pathway following the loss of IFNg through an increased IL17 response. This study is not cited nor discussed even though it may alter the interpretation of several experiments.</p></disp-quote><p>Thank you for pointing out this earlier study, which we concede, we missed discussing. We disagree on the point that results from that study may alter the interpretation of several experiments in our study. On the contrary, the main observation that loss of IFNγ causes severe IL-17 levels is aligned in both studies.</p><p>IDO1 is known to alter T-helper cell differentiation towards Tregs and away from Th17 (Baban et al. 2009). It is absolutely feasible for the non-hematopoietic cells to regulate these events. However, that does not rule out the neutrophil production of IL-17 and the downstream pathological effect shown in this study. We have discussed and cited this study in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Several of the key findings in mice have previously been shown (albeit with less sophisticated experimentation) and human disease and neutrophils are well described - thus the real new finding is how intracellular Mtb in neutrophils are more refractory to BCG-mediated control. However, given there are already high levels of Mtb in PMNs compared to other cell types, and there is a decrease in intracellular Mtb in PMNs following BCG immunization the strength of this finding is a bit limited.</p></disp-quote><p>The reviewer’s interpretation of the BCG-refractory Mtb population in the neutrophil is interesting. The reviewer is right that neutrophils had a higher intracellular Mtb burden, which decreased in the BCG-vaccinated animals. Thus, on that account, the reviewer rightly mentions that BCG is able to control Mtb even in neutrophils. However, BCG almost clears intracellular burden from other cell types analysed, and therefore, the remnant pool of intracellular Mtb in the lungs of BCG-vaccinated animals could be mostly those present in the neutrophils. This is a substantial novel development in the field and attracts focus towards innate immune cells for vaccine efficacy.</p><p>References:</p><p>Appelberg, R., A. G. Castro, S. Gomes, J. Pedrosa, and M. T. Silva. 1995. 'SuscepBbility of beige mice to Mycobacterium avium: role of neutrophils', Infect Immun, 63: 3381-7.</p><p>Baban, B., P. R. Chandler, M. D. Sharma, J. Pihkala, P. A. Koni, D. H. Munn, and A. L. Mellor. 2009. 'IDO acBvates regulatory T cells and blocks their conversion into Th17-like T cells', J Immunol, 183: 2475-83.</p><p>Choi, H. G., K. W. Kwon, S. Choi, Y. W. Back, H. S. Park, S. M. Kang, E. Choi, S. J. Shin, and H. J. Kim. 2020. 'AnBgen-Specific IFN-gamma/IL-17-Co-Producing CD4(+) T-Cells Are the Determinants for ProtecBve Efficacy of Tuberculosis Subunit Vaccine', Vaccines (Basel), 8.</p><p>Cruz, A., A. G. Fraga, J. J. Fountain, J. Rangel-Moreno, E. Torrado, M. Saraiva, D. R. Pereira, T. D. Randall, J. Pedrosa, A. M. Cooper, and A. G. Castro. 2010. 'Pathological role of interleukin 17 in mice subjected to repeated BCG vaccinaBon afer infecBon with <italic>Mycobacterium tuberculosis</italic>', J Exp Med, 207: 1609-16.</p><p>Desel, C., A. Dorhoi, S. Bandermann, L. Grode, B. Eisele, and S. H. Kaufmann. 2011. 'Recombinant BCG DeltaureC hly+ induces superior protecBon over parental BCG by sBmulaBng a balanced combinaBon of type 1 and type 17 cytokine responses', J Infect Dis, 204: 1573-84.</p><p>Desvignes, L., and J. D. Ernst. 2009. 'Interferon-gamma-responsive nonhematopoieBc cells regulate the immune response to <italic>Mycobacterium tuberculosis</italic>', Immunity, 31: 974-85.</p><p>Ferreg, S., O. Bonneau, G. R. Dubois, C. E. Jones, and A. Trifilieff. 2003. 'IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger', J Immunol, 170: 2106-12.</p><p>Hellebrekers, P., N. Vrisekoop, and L. Koenderman. 2018. 'Neutrophil phenotypes in health and disease', Eur J Clin Invest, 48 Suppl 2: e12943.</p><p>Hoshino, A., T. Nagao, N. Nagi-Miura, N. Ohno, M. Yasuhara, K. Yamamoto, T. Nakayama, and K. Suzuki. 2008. 'MPO-ANCA induces IL-17 producBon by acBvated neutrophils in vitro via classical complement pathway-dependent manner', J Autoimmun, 31: 79-89.</p><p>Hu, S., W. He, X. Du, J. Yang, Q. Wen, X. P. Zhong, and L. Ma. 2017. 'IL-17 ProducBon of Neutrophils Enhances AnBbacteria Ability but Promotes ArthriBs Development During <italic>Mycobacterium tuberculosis</italic> InfecBon', EBioMedicine, 23: 88-99.</p><p>Hult, C., J. T. Magla, H. P. Gideon, J. J. Linderman, and D. E. Kirschner. 2021. 'Neutrophil Dynamics Affect <italic>Mycobacterium tuberculosis</italic> Granuloma Outcomes and DisseminaBon', Front Immunol, 12: 712457.</p><p>Katayama, M., K. Ohmura, N. Yukawa, C. Terao, M. Hashimoto, H. Yoshifuji, D. Kawabata, T. Fujii, Y. Iwakura, and T. Mimori. 2013. 'Neutrophils are essenBal as a source of IL-17 in the effector phase of arthriBs', PLoS One, 8: e62231.</p><p>Khader, S. A., G. K. Bell, J. E. Pearl, J. J. Fountain, J. Rangel-Moreno, G. E. Cilley, F. Shen, S. M. Eaton, S. L. Gaffen, S. L. Swain, R. M. Locksley, L. Haynes, T. D. Randall, and A. M. Cooper. 2007. 'IL-23 and IL-17 in the establishment of protecBve pulmonary CD4+ T cell responses afer vaccinaBon and during <italic>Mycobacterium tuberculosis</italic> challenge', Nat Immunol, 8: 369-77.</p><p>Leliefeld, P. H. C., J. Pillay, N. Vrisekoop, M. Heeres, T. Tak, M. Kox, S. H. M. Rooijakkers, T. W. Kuijpers, P. Pickkers, L. P. H. Leenen, and L. Koenderman. 2018. 'DifferenBal anBbacterial control by neutrophil subsets', Blood Adv, 2: 1344-55.</p><p>Lemos, H. P., R. Grespan, S. M. Vieira, T. M. Cunha, W. A. Verri, Jr., K. S. Fernandes, F. O. Souto, I. B. McInnes, S. H. Ferreira, F. Y. Liew, and F. Q. Cunha. 2009. 'Prostaglandin mediates IL-23/IL-17induced neutrophil migraBon in inflammaBon by inhibiBng IL-12 and IFNgamma producBon', Proc Natl Acad Sci U S A, 106: 5954-9.</p><p>Li, L., L. Huang, A. L. Vergis, H. Ye, A. Bajwa, V. Narayan, R. M. Strieter, D. L. Rosin, and M. D. Okusa. 2010. 'IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migraBon in mouse kidney ischemia-reperfusion injury', J Clin Invest, 120: 331-42.</p><p>Lin, A. M., C. J. Rubin, R. Khandpur, J. Y. Wang, M. Riblen, S. Yalavarthi, E. C. Villanueva, P. Shah, M. J. Kaplan, and A. T. Bruce. 2011. 'Mast cells and neutrophils release IL-17 through extracellular trap formaBon in psoriasis', J Immunol, 187: 490-500.</p><p>Lovewell, R. R., C. E. Baer, B. B. Mishra, C. M. Smith, and C. M. Sasseg. 2021. 'Granulocytes act as a niche for <italic>Mycobacterium tuberculosis</italic> growth', Mucosal Immunol, 14: 229-41.</p><p>Lyadova, I. V. 2017. 'Neutrophils in Tuberculosis: Heterogeneity Shapes the Way?', Mediators Inflamm, 2017: 8619307.</p><p>Mishra, B. B., R. R. Lovewell, A. J. Olive, G. Zhang, W. Wang, E. Eugenin, C. M. Smith, J. Y. Phuah, J. E. Long, M. L. Dubuke, S. G. Palace, J. D. Goguen, R. E. Baker, S. Nambi, R. Mishra, M. G. Booty, C. E. Baer, S. A. Shaffer, V. Dartois, B. A. McCormick, X. Chen, and C. M. Sasseg. 2017. 'Nitric oxide prevents a pathogen-permissive granulocyBc inflammaBon during tuberculosis', Nat Microbiol, 2: 17072.</p><p>Napolitani, G., E. V. Acosta-Rodriguez, A. Lanzavecchia, and F. Sallusto. 2009. 'Prostaglandin E2 enhances Th17 responses via modulaBon of IL-17 and IFN-gamma producBon by memory CD4+ T cells', Eur J Immunol, 39: 1301-12.</p><p>Nwongbouwoh Muefong, C., O. Owolabi, S. Donkor, S. Charalambous, A. Bakuli, A. Rachow, C. Geldmacher, and J. S. Sutherland. 2022. 'Neutrophils Contribute to Severity of Tuberculosis</p><p>Pathology and Recovery From Lung Damage Pre- and Posnreatment', Clin Infect Dis, 74: 175766.</p><p>Paulissen, S. M., J. P. van Hamburg, N. Davelaar, P. S. Asmawidjaja, J. M. Hazes, and E. Lubberts. 2013. 'Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23', J Immunol, 191: 1364-72.</p><p>Pedrosa, J., B. M. Saunders, R. Appelberg, I. M. Orme, M. T. Silva, and A. M. Cooper. 2000. 'Neutrophils play a protecBve nonphagocyBc role in systemic <italic>Mycobacterium tuberculosis</italic> infecBon of mice', Infect Immun, 68: 577-83.</p><p>Polese, B., B. Thurairajah, H. Zhang, C. L. Soo, C. A. McMahon, G. Fontes, S. N. A. Hussain, V. Abadie, and I. L. King. 2021. 'Prostaglandin E(2) amplifies IL-17 producBon by gammadelta T cells during barrier inflammaBon', Cell Rep, 36: 109456.</p><p>Rankin, A. N., S. V. Hendrix, S. K. Naik, and C. L. Stallings. 2022. 'Exploring the Role of Low-Density Neutrophils During <italic>Mycobacterium tuberculosis</italic> InfecBon', Front Cell Infect Microbiol, 12: 901590.</p><p>Xu, X. J., Q. Q. Ge, M. S. Yang, Y. Zhuang, B. Zhang, J. Q. Dong, F. Niu, H. Li, and B. Y. Liu. 2023. 'Neutrophil-derived interleukin-17A parBcipates in neuroinflammaBon induced by traumaBc brain injury', Neural Regen Res, 18: 1046-51.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>All figures: Clear information about the number of repeat experiments for each figure must be included.</p></disp-quote><p>We have provided the details of the number of repeat experiments in the revised version.</p><disp-quote content-type="editor-comment"><p>Figure 1: The claim that neutrophils are a dominant cell type infected during Mtb infection of the lungs is undermined by the limited number of markers used to identify cell types. The gating strategy used to initially identify what cells are infected with Mtb divided cells into three categories; granulocytes (Ly6G<sup>+</sup> Cd11b<sup>+</sup>), CD64+MerTK+ macrophages, or Sca1+CD90.1+CD73+ (mesenchymal stem cells). This strategy leaves out monocyte populations that have been shown to be the dominant infected cells in other strategies (most recently, PMID: 36711606).</p></disp-quote><p>Thank you for this important point. We agree that we did not assess the infected monocyte population, specifically the Cd11c<sup>+</sup> population. Both CD11c<sup>Hi</sup> and CD11c<sup>Lo</sup> monocyte cells appear to be important for Mtb infection, in different studies (Lee et al., 2020), (Zheng et al., 2024). Therefore, leaving out the CD11c<sup>+</sup> population in our assays was a conscious decision to ensure the clarity of the cell types being studied.</p><p>In addition, substantial evidence from multiple studies indicates that Ly6G⁺ granulocytes constitute the predominant infected population in the Mtb-infected lungs of both mice and humans (Lovewell et al., 2021) (Eum et al., 2010). While monocytes may contribute to Mtb infection dynamics, our findings align with a growing body of research emphasizing the significant role of neutrophils as a dominant infected cell type in the lungs during TB pathology.</p><disp-quote content-type="editor-comment"><p>Figure 1: Putting the data from separate panels together, it appears that very few bacteria are isolated from the three cell types in the lung, suggesting there may be some loss in the preparation steps. Why is the total sorted CFU from neutrophils, macrophages, and MSCs so low, &lt;400 bacteria total, when the absolute CFU is so high? Is it because only a fraction of the lung is being sorted/plated?</p></disp-quote><p>Yes, only a fraction of the lung was used for cell sorting and subsequent plating. The CFU plating from sorted cells also does not account for any bacteria growing extracellularly.</p><disp-quote content-type="editor-comment"><p>Figure 3C: It is difficult to ascertain whether the gating on IL-17<sup>+</sup> cells is accurately identifying IL-17 producing cells. It is surprising, based on other published work, that the authors claim that almost half of CD45+CD11b-Ly6G- cells produce IL-17 in WT mice. It would be informative to show cell type-specific production of IL-17 in both WT and IFN-γ KO mice for comparison with the literature. Unstained/isotype controls for IL-17 staining should be shown. With this in mind, it is difficult to interpret the authors' claim that 80% of neutrophils produce IL-17.</p></disp-quote><p>Thank you for the points above. We do agree that we were surprised to see ~50% of CD45<sup>+</sup> CD11b<sup>-</sup>Ly6G<sup>-</sup> cells producing IL-17. We have now done multiple experiments to confirm that this number is actually less than 1% (~90 cells) in the uninfected mice and less than 4% (~4000) in the Mtb-infected mice.</p><p>Neutrophil-derived IL-17 production in Mtb-infected lungs is supported by two independent techniques in our current study: Flow Cytometry and Immunofluorescence assay. While Neutrophil production of IL-17 is rarely studied in the context of TB, in several other settings it has been widely reported (Gonzalez-Orozco et al., 2019; Li et al., 2010; Ramirez-Velazquez et al., 2013). We consistently get &gt;60% IL-17 positive cells in the CD11b<sup>+</sup> Ly6G<sup>+</sup> population, specifically in the infected samples.</p><p>To specifically address the reviewer’s concerns, we have now used an isotype control for IL17 staining and show the specificity of IL-17A antibody binding. The Author response image 1 is from the uninfected mice, 8 weeks age.</p><p>Unfortunately, our efforts to establish an IL-17 ELISPOT assay from neutrophils were not very successful and need further standardisation. The new results are included in Fig. 3C-D and Fig. S2F-G in the revised manuscript.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100966-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Figure 3 D-H. Quantification of immunofluorescence microscopy should be provided.</p></disp-quote><p>In the revised manuscript, we provide the quantification of IFA results.</p><disp-quote content-type="editor-comment"><p>Figure 4: Effects on neutrophil numbers in IFN-γ Kos do not correlate with CFU reductions, suggesting there may be a neutrophilindependent mechanism.</p></disp-quote><p>In the IFN-γ KO, we agree that the effect was less than dramatic. The immune dysfunction in the IFN-γ KO mice is too severe to see a strong reversal in the phenotype through interventions.</p><p>While we do not rule out any neutrophil-independent mechanism, in the context of following observations, neutrophil-dependent mechanisms certainly appear to play an important role-</p><p>(a) Improved pathology and survival upon IL-17 neutralization, which further improves with the inclusion of celecoxib.</p><p>(b) Loss of IL17<sup>+</sup>-Ly6G<sup>+</sup> cells upon IL-17 neutralization, which is further exacerbated when combined with celecoxib.</p><p>(c) Significant reduction in PMN number (shown by FACS) without any major impact on Th17 cell population upon IL-17 neutralization.</p><p>Finally, we believe some of the observations may become stronger once we characterize the specific sub-population among the Ly6G+ cells that correlates with pathology. For example, as shown in Figure 4I, FACS analysis of the Ly6G<sup>⁺</sup> cell population in Mtb-infected IFNγ<sup>⁻/⁻</sup> mice revealed a substantial subset of CD11b<sup>mid</sup> Ly6G<sup>ʰⁱ</sup> cells, indicative of an immature neutrophil population (Scapini et al., 2016). Efforts are currently underway to identify these important subpopulations.</p><disp-quote content-type="editor-comment"><p>Figure 4: Differences observed in the spleen cannot be connected to dissemination per se but instead could be a result of enhanced immune control in the spleen.</p></disp-quote><p>Thank you for this important point. We have revised this section. The role of neutrophils in Mtb dissemination is an emerging area of research, with growing evidence suggesting that these cells contribute to the spread of Mtb beyond the lungs (Hult et al., 2021). We highlight that the observed correlation could be speculative at this juncture.</p><disp-quote content-type="editor-comment"><p>Figure 4, 5: IL-17 neutralization alone has no effect on CFU in the lungs of Mtb-infected mice. While the combination of IL-17 neutralization and celecoxib has a very modest effect on CFU, the mechanism behind this observation is unclear. Further, the experiment shown has only 3 mice per group and it is unclear whether this (or any other) mouse experiment was repeated.</p></disp-quote><p>For Fig. 4, the experiment was done with 3 mice/group. The IFN KO mice were used to help identify the mechanism. IL-17 neutralisation or Celecoxib treatment alone did not have any significant effect on the bacterial burden (in lungs or isolated PMNs). However, it did show a significant effect on the number of PMNs recruited. Combination of IL-17 neutralisation and celecoxib led to about a one-log decrease in CFU, which is significant.</p><p>For Fig. 5, we used SR2211 instead of anti-IL-17 Ab for the experiment. This experiment had WT mice and 5 animals/group. Here, celecoxib and SR2211 alone showed a significant decline in PMN-resident Mtb pool as well as spleen burden. Only in the lungs, the impact of SR2211 alone was not significant.</p><disp-quote content-type="editor-comment"><p>Figure 6: The decreases in CFU correlate with a decrease in neutrophils; nothing connects this to neutrophil production of IL-17.</p></disp-quote><p>We now show quantification of observation in Fig. 5I, where in the WT mice, treatment with Celecoxib reduces the frequency of IL-17-producing Ly6G+ cells. In the revised manuscript, we also show direct evidence of SR2211 activity on BCG vaccine efficacy, which causes a significant decline in the Mtb burden in whole lung or in the isolated PMNs.</p><disp-quote content-type="editor-comment"><p>Figure 7. The Human data shows that elevated neutrophil levels and elevated IL-17 levels are associated with treatment failure in TB patients. This is expected, and does not</p></disp-quote><p>The literature lacks consensus in terms of a protective or pathological role of IL-17 in TB. Therefore, it was not expected to see higher IL-17 in patients who experienced relapse, death, or failed treatment outcomes. We do not have evidence from human subjects whether neutrophil derived IL-17 has a similar pathological role as observed in mice. However, higher IL-17 in failed outcome cases confirm the central theme that IL-17 is pathological in both human and mouse models.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) Survival of IFN-γ-/- Mice: The survival of IFN-γ-/- mice up to 100 days following a challenge with ~100 CFU of H37Rv is quite unusual. Have the authors checked PDIM expression in their Mtb strain, given that several studies report earlier mortality in these mice?</p></disp-quote><p>As shown in Fig. 4F, H37Rv-infected IFN-γ⁻/⁻ mice survived up to a little over 80 days. These figures are not unusual in the light of the following:</p><p>(1) In one study, IFNγ⁻/⁻ survived for about 40 days when the hypervirulent Mtb strain was used to infect these mice at 100-200 CFU using nose-only aerosol exposure (Nandi and Behar, 2011)</p><p>(2) In yet another study, IFNγ⁻/⁻ mice survived for ~50 days, however, they used H37Rv at 1-3x10<sup>5</sup> CFU to infect through intravenous injection (Kawakami et al., 2004)</p><p>Thus, compared with the above observations, where IFN-γ<sup>-/-</sup> mice survived for maximum 50 days due to hypervirulent infection or a very high dose infection, infection with H37Rv at ~100 CFU through the aerosol route and surviving for ~80 days is not unusual. The H37Rv cultures used in our study are always animal-passaged to ensure PDIM integrity.</p><disp-quote content-type="editor-comment"><p>(2) Granuloma Scoring: The granuloma scores appear to represent the percentage of lesion area. Please clarify and, if necessary, amend this in the manuscript.</p></disp-quote><p>The granuloma score is based on the calculation of the number of granulomatous infiltration and their severity. These are not % lesion area. We have added this detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3) Pathology Comparison in Figures 4F and 4G: Does the pathology shown in Figure 4G correspond to the same groups as in Figure 4F? The celecoxib group in Figure 4F and the WT group in Figure 4G seem to be missing. Please clarify.</p></disp-quote><p>Figures 4F and 4G depict two independent experiments. For the time-to-death experiment, we had to leave the animals. The rest of the panels in Fig. 4 represent animals from the same experiment.</p><disp-quote content-type="editor-comment"><p>(4) Effect of Celecoxib on Ly6G+ Cells: The authors demonstrated that celecoxib treatment reduces Ly6G+ cells and IL-17-producing Ly6G+ cells. Do Ly6G+ cells express EP2/EP4 receptors? Alternatively, could the reduction in IL-17-producing Ly6G+ cells be due to an improved bactericidal response in other innate cells? The authors should discuss this possibility.</p></disp-quote><p>Yes, Ly6G<sup>⁺</sup> granulocytes express EP2/EP4 receptors (Lavoie et al., 2024), which mediate PGE₂ signaling. Prostaglandin E<sub>₂</sub> (PGE<sub>₂</sub>) is known to regulate neutrophil function and can enhance IL-17 production in various immune cells (Napolitani et al., 2009). However, the expression and functional role of EP2/EP4 receptors specifically on Ly6G<sup>⁺</sup> granulocytes in the context of Mtb infection require further investigation.</p><p>The alternate suggestion by the reviewer that the reduction in IL-17-producing Ly6G<sup>⁺</sup> cells following celecoxib treatment could be attributed to an improved bactericidal response in other innate immune cells is attractive. While we did not experimentally rule out this possibility, since reduced IL-17 invariably associated with reduced neutrophil-resident Mtb population, a cell-autonomous mechanism operational in Ly6G+ granulocytes is a highly likely mechanism.</p><disp-quote content-type="editor-comment"><p>(5) Culture Conditions: The methods section indicates that bacteria were cultured in 7H9+ADC. Is there a specific reason why the Oleic acid supplement was not added, given that standard Mtb culture conditions typically use 7H9+OADC supplements? Please comment on this choice.</p></disp-quote><p>It is a standard microbiological experimental procedure to use 7H9+ADC for broth culture, while 7H11+OADC for solid culture. Compared to broth culture, solid media are usually more stressful for bacteria because of hypoxia inside the growing colonies. Therefore, the media used are enriched in casein hydrolysate (like 7H11) and oleic acid (OADC).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Major suggestion: To really determine the role of neutrophil IL17 will require depletion studies and chimera experiments. These are clearly a major undertaking. I believe making significant re-writes to alter the conclusions or reanalyze any data to determine the role of nonhematopoietic and hematopoietic cells in IL17 is needed. If the conclusions are left as is, further experimentation is needed to fully support those conclusions.</p></disp-quote><p>Thank you for the suggestion. We have embarked on the specific deletion studies; however, as mentioned, this is a major undertaking and will take time. As suggested, we have discussed the results in accordance with the strength of evidence currently provided.</p><p>Eum, S.Y., J.H. Kong, M.S. Hong, Y.J. Lee, J.H. Kim, S.H. Hwang, S.N. Cho, L.E. Via, and C.E. Barry, 3rd. 2010. Neutrophils are the predominant infected phagocyGc cells in the airways of paGents with acGve pulmonary TB. Chest 137:122-128.</p><p>Gonzalez-Orozco, M., R.E. Barbosa-Cobos, P. Santana-Sanchez, L. Becerril-Mendoza, L. Limon-</p><p>Camacho, A.I. Juarez-Estrada, G.E. Lugo-Zamudio, J. Moreno-Rodriguez, and V. OrGzNavarrete. 2019. Endogenous sGmulaGon is responsible for the high frequency of IL-17Aproducing neutrophils in paGents with rheumatoid arthriGs. Allergy Asthma Clin Immunol 15:44.</p><p>References</p><p>Hult, C., J.T. Mala, H.P. Gideon, J.J. Linderman, and D.E. Kirschner. 2021. Neutrophil Dynamics Affect <italic>Mycobacterium tuberculosis</italic> Granuloma Outcomes and DisseminaGon. Front Immunol 12:712457.</p><p>Kawakami, K., Y. Kinjo, K. Uezu, K. Miyagi, T. Kinjo, S. Yara, Y. Koguchi, A. Miyazato, K. Shibuya, Y. Iwakura, K. Takeda, S. Akira, and A. Saito. 2004. Interferon-gamma producGon and host protecGve response against <italic>Mycobacterium tuberculosis</italic> in mice lacking both IL-12p40 and IL-18. Microbes Infect 6:339-349.</p><p>Lavoie, J.C., M. Simard, H. Kalkan, V. Rakotoarivelo, S. Huot, V. Di Marzo, A. Cote, M. Pouliot, and N. Flamand. 2024. Pharmacological evidence that the inhibitory effects of prostaglandin E2 are mediated by the EP2 and EP4 receptors in human neutrophils. J Leukoc Biol 115:1183-1189.</p><p>Lee, J., S. Boyce, J. Powers, C. Baer, C.M. Sasse, and S.M. Behar. 2020. CD11cHi monocyte-derived macrophages are a major cellular compartment infected by <italic>Mycobacterium tuberculosis</italic>. PLoS Pathog 16:e1008621.</p><p>Li, L., L. Huang, A.L. Vergis, H. Ye, A. Bajwa, V. Narayan, R.M. Strieter, D.L. Rosin, and M.D. Okusa. 2010. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migraGon in mouse kidney ischemia-reperfusion injury. J Clin Invest 120:331-342.</p><p>Lovewell, R.R., C.E. Baer, B.B. Mishra, C.M. Smith, and C.M. Sasse. 2021. Granulocytes act as a niche for <italic>Mycobacterium tuberculosis</italic> growth. Mucosal Immunol 14:229-241.</p><p>Nandi, B., and S.M. Behar. 2011. RegulaGon of neutrophils by interferon-gamma limits lung inflammaGon during tuberculosis infecGon. The Journal of experimental medicine 208:22512262.</p><p>Napolitani, G., E.V. Acosta-Rodriguez, A. Lanzavecchia, and F. Sallusto. 2009. Prostaglandin E2 enhances Th17 responses via modulaGon of IL-17 and IFN-gamma producGon by memory CD4+ T cells. Eur J Immunol 39:1301-1312.</p><p>Ramirez-Velazquez, C., E.C. CasGllo, L. Guido-Bayardo, and V. OrGz-Navarrete. 2013. IL-17-producing peripheral blood CD177+ neutrophils increase in allergic asthmaGc subjects. Allergy Asthma Clin Immunol 9:23.</p><p>Sadikot, R.T., H. Zeng, A.C. Azim, M. Joo, S.K. Dey, R.M. Breyer, R.S. Peebles, T.S. Blackwell, and J.W. Christman. 2007. Bacterial clearance of <italic>Pseudomonas aeruginosa</italic> is enhanced by the inhibiGon of COX-2. Eur J Immunol 37:1001-1009.</p><p>Zheng, W., I.C. Chang, J. Limberis, J.M. Budzik, B.S. Zha, Z. Howard, L. Chen, and J.D. Ernst. 2023. <italic>Mycobacterium tuberculosis</italic> resides in lysosome-poor monocyte-derived lung cells during chronic infecGon. bioRxiv</p><p>Zheng, W., I.C. Chang, J. Limberis, J.M. Budzik, B.S. Zha, Z. Howard, L. Chen, and J.D. Ernst. 2024. <italic>Mycobacterium tuberculosis</italic> resides in lysosome-poor monocyte-derived lung cells during chronic infecGon. PLoS Pathog 20:e1012205.</p></body></sub-article></article>